METHOD FOR EVALUATING THE EFFICACY OF AN AEROSOL FOR PULMONARY DRUG TRANSPORT AND INHALATOR DEVICE, ORALLY INHALATED AND / OR NASAL DRUG PRODUCT AND DRUG / DEVICE COMBINATION PRODUCT
A numerical modeling approach for pulmonary drug delivery evaluates aerosol effectiveness by simulating aerosol transport in patient-specific respiratory systems, addressing inaccuracies in existing methods and enhancing precision and safety in inhaler design and drug delivery.
Patent Information
- Application Number
- DE102023114221
- Authority / Receiving Office
- DE · DE
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2023-05-31
- Publication Date
- 2024-12-05
AI Technical Summary
Existing methods for evaluating pulmonary drug delivery to the lungs are inaccurate and inefficient, failing to predict the dose delivered to the site of action due to variations in inhaler design, patient physiology, and lung morphology, particularly in diseases like COPD or IPF, and lack comprehensive modeling of the respiratory system.
A method using a numerical lung model derived from processed image data of the respiratory system, combined with a particle transport and deposition model, to calculate the spatial distribution of aerosol particles and evaluate pulmonary drug transport effectiveness, considering transient gas flow and individual aerosol parameters.
Enables precise prediction and evaluation of drug transport to specific lung areas, reducing radiation exposure and improving accuracy by accounting for individual patient-specific geometry and lung diseases, facilitating improved inhaler design and drug product development.
Smart Images

Figure 00000000_0000_ABST
Abstract
Description
Technical area
[0001] The invention relates to a method for evaluating the efficacy of an aerosol for pulmonary drug delivery. Furthermore, the invention relates to an inhaler and / or ventilator for administering orally inhaled and / or nasal drug products, an orally inhaled and / or nasal drug product, and a drug / device combination product comprising such a drug product and such a device.
[0002] Furthermore, the invention relates to the evaluation of the efficacy of an orally inhaled and / or nasal drug product and a drug / device combination product for pulmonary drug delivery, as well as to the evaluation of the performance of an inhaler device and / or a ventilator device for pulmonary drug delivery. The invention also relates to methods for generating an aerosol, for designing and / or manufacturing an inhaler device and / or a ventilator device, and for manufacturing an orally inhaled and / or nasal drug product. background
[0003] The administration of drugs into the lungs (pulmonary drug transport) is a beneficial and important route of drug delivery. However, the major challenge is that the dose delivered to the site of action in the lungs (and thereafter) is unpredictable and difficult to measure retrospectively. The delivered dose primarily determines the efficacy of pulmonary drug transport.
[0004] Different types of inhaler devices are typically used to deliver different types of orally inhaled medications. Among other factors, the properties of the aerosol generated by the inhaler device significantly influence the transport of aerosol particles to the lungs and thus the effectiveness of pulmonary drug delivery.
[0005] The locally delivered drug dose is unpredictable in practice, as aerosol transport and deposition depend on a multitude of factors, ranging from the inhaler design and inhalation pattern to the type of aerosol and patient constitution. It can vary dramatically both between subjects and within the lung, depending on lung morphology / physiology and the disease, as lungs affected by diseases such as COPD or IPF no longer have a homogeneous air distribution but exhibit strong regional variations. It is therefore desirable to provide orally inhaled drug products, inhaler devices, and drug / device combination products that achieve predictable efficacy of pulmonary drug transport.
[0006] Numerous devices for delivering medication into the lungs are currently available on the market. The most common inhaler devices available fall into three main categories. Metered-dose inhalers (MDIs) include pressurized metered-dose inhalers (pMDIs) and breath-actuated metered-dose inhalers (BAMDIs). Dry powder inhalers (DPIs) include single-dose dry powder inhalers, multiple unit-dose dry powder inhalers, and multi-dose dry powder inhalers. Soft-mist inhalers (SMIs) include vibrating mesh nebulizers (VMNs), jet nebulizers (JNs), and ultrasonic nebulizers.
[0007] Metered-dose inhalers (MDIs) are commonly used to treat respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). Their ease of use, portability, and rapid relief of respiratory symptoms make them a popular choice. However, correct technique is critical for effective medication delivery, and some patients may find MDIs difficult to use correctly. Pressurized metered-dose inhalers (pMDIs) have a canister containing a pressurized medication formulation and a mouthpiece through which the medication is inhaled. The medication is released when the patient presses the canister, whether the patient is inhaling or not. The effectiveness of medication delivery with MDIs can depend on the patient's coordination and ability to inhale at the correct moment.Breath-activated metered-dose inhalers (BAMDIs), on the other hand, deliver medication only when the patient actively inhales. This eliminates the need for patient coordination in releasing the medication and inhaling simultaneously.
[0008] Dry powder inhalers (DPIs) are medical devices that deliver medication directly to the lungs. Unlike MDIs, which deliver the medication in a mist, DPIs deliver the medication in a dry powder form. DPIs also do not require patient coordination, as they release the medication only during inhalation, simplifying their use. A disadvantage is that the medication dosage is not consistent due to slight variations with each inhalation. Generally, three different types of DPIs are available. Unit-dose DPIs contain a single dose of medication in a pre-measured capsule. Upon use, this capsule is pierced, the medication dispenses, and the inhaler is discarded. Multi-unit-dose DPIs contain multiple doses of medication, which are punctured like unit-dose DPIs. These inhalers are discarded once all doses have been used.Multi-dose DPIs contain a reservoir of medication that is measured with each use. The medication can also be refilled when the inhaler is empty.
[0009] Soft-mist inhalers (SMIs), also called nebulizer inhalers, use a mechanical system to generate a mist that is inhaled by patients. Because the generation of the mist does not depend on the patient's inhalation, SMIs are often used for patients who have difficulty using an MDI or DPI. Disadvantages of SMIs include long treatment times, large, non-portable devices, the need for external power sources, regular cleaning and maintenance, and the high price of the device. Among soft-mist inhalers, vibrating mesh nebulizers (VMNs) use a vibrating mesh membrane to convert liquid medication into a fine mist that can be inhaled. They can be further divided into active and passive vibrating mesh nebulizers. Jet nebulizers (JNs) use a high-pressure gas flow onto a liquid medication reservoir.Due to the high flow velocity and surface tension of the liquid, it is converted into small droplets. Larger droplets are deflected and further atomized by the airflow before exiting the nebulizer. Other types of jet nebulizers include vented nebulizers and breath-enhanced nebulizers. Ultrasonic nebulizers use a piezoelectric crystal to generate high-frequency vibrations that convert the liquid medication into a fine mist that is inhaled by the patient.
[0010] In addition to the three main categories, there are other types of inhalers, such as rotating disc aerosol generators, rotating top aerosol generators, or centrifugal aerosol generators. These types use a rapidly rotating disc with embedded grooves to generate aerosol particles from a medication reservoir. Due to the high rotation speed and the resulting centrifugal force, the medication is compressed into a thin film, broken up into fine droplets, and eventually exits the rotating disc. The fine mist is then carried away by an air stream.
[0011] Due to the geometric complexity of the (human) respiratory system, including the lungs—hereafter often referred to simply as the lungs—experimental investigations using physical models of the lungs or parts thereof are only possible in highly simplified systems, and even then, experiments are notoriously difficult to conduct. Suitable animal models are also difficult to develop and are associated with ethical and other disadvantages. In vivo imaging of aerosol inhalation and deposition in humans is possible using modern nuclear imaging techniques such as radioscintigraphy or 3D SPECT imaging. However, these imaging techniques have limited spatial and temporal resolution, due, among other things, to motion artifacts or depth-dependent spatial blur. Furthermore, their use in sensitive populations is often not possible or ethically justifiable.
[0012] In silico modeling techniques for simulating a specific patient's pulmonary system were considered as an alternative, and several numerical approaches have been developed to approximate particle transport in human lungs. However, existing models are severely limited by morphological truncation, i.e., they do not encompass the entire airway tree and lack spatial resolution. Furthermore, existing models do not consider lung tissue, nor the rib cage and diaphragm.
[0013] Before discussing existing modeling approaches in more detail, it is important to clarify certain terms related to the spatial distribution and deposition of particles within the lung. The relevant literature commonly uses the term "regional" deposition in the lung, which typically involves a distinction between larger subregions of the pulmonary system such as the oropharyngeal region, the tracheal-bronchial region, and the distinction between lung lobes or specific airway generations (levels of airway branching of the lung). In contrast, the inventive modeling approach can achieve much higher resolution and predict the precise trajectory of all particles both spatially and temporally. Therefore, we use the term "spatiotemporal" to refer to patterns in space and time and the term "regional" to refer to different compartments and subdomains within the pulmonary system.
[0014] However, known modeling approaches for pulmonary drug transport vary widely and depend on the specific application and purpose of the model. Historically, three approaches have dominated the simulation of drug delivery to the lungs. More specifically, the physical phenomena governing particle transport and deposition can be encapsulated in a numerical particle transport and deposition model by deriving the mathematical equations either empirically, heuristically, or from first principles—that is, from the physical laws governing particle transport in the lungs.
[0015] The so-called ICRP model (The New ICRP Model for the Respiratory Tract. Radiation Protection Dosimetry. 1994; 53(1-4):107-114. doi:10.1093 / rpd / 53.1-4.107) is an example of an empirical model. Essentially, the model comprises a series of mathematical filter functions with empirically determined deposition fractions for different regions within the lung. Empirical models neglect the complex geometric structure of the lung and therefore cannot account for the patient-specific geometry of the lung or airways, nor for damage to lung tissue in specific subdomains.
[0016] The situation is similar with trumpet models (see Taulbee DB, Yu CP. A theory of aerosol deposition in the human respiratory tract. Journal of Applied Physiology. 1975; 38(1):77-85. doi:10.1152 / jappl.1975.38.1.77, Taulbee DB, Yu CP, Heyder J. Aerosol transport in the human lung from analysis of single breaths. Journal of Applied Physiology 1978; 44(5):803-812. doi:10.1152 / jappl. doi:10.1080 / 027868201300034844) that approximate the human airway system through a one-dimensional channel with variable cross-section. Particle transport and deposition are described by differential equations in a one-dimensional channel that accounts for the increasing volume of the airways with generation but neglects all internal structures of the lung.Although the model impresses with its simplicity and elegance, the crude geometric simplification of the trumpet model precludes its application to individual patients.
[0017] In contrast, heuristic models contain some information about the geometry of the airway tree. Therefore, these models are often referred to as morphometric models. Examples of this class of models are single-path (typical path) models (Human respiratory tract model for radiological protection. A report of a Task Group of the International Commission on Radiological Protection. Ann ICRP. 1994; 24(1-3):1-482.) or multi-path models, such as MPPD (Asgharian B, Hofmann W, Bergmann R. Particle Deposition in a Multiple-Path Model of the Human Lung. Aerosol Science and Technology. 2001; 34(4):332-339. doi:10.1080 / 02786820119122).
[0018] In these models, the calculation of the airflow distribution in the lungs is not based on physical principles, but on heuristic assumptions such as the division of flow proportional to the distal lung volume supplied by the two airways. This assumption is clearly violated in almost all cases where the conducting or respiratory airways are affected by disease and exhibit pathological abnormalities. Furthermore, these models are not well suited to modeling patient-specific drug transport and deposition. Therefore, these models are only suitable for studies seeking a broad understanding of the phenomena of particle deposition in a large cohort of relatively healthy lungs, as these models are unable to reveal specific particle deposition sites (e.g., hotspots) and cannot account for complex flow patterns within the airway system.Another limitation of these models is that they were designed to simulate the deposition of environmental particles, which does not reflect the situation of inhalation of aerosols from sprays.
[0019] At the other end of the spectrum are physically based Computational Fluid Particle Dynamics (CFPD) models, which are based on physically based equations and actual or idealized patient-specific geometries.
[0020] EP 2 255 843 A1 describes such an approach, in which the geometry of the first generations of the airways is extracted from a CT scan (computed tomography), meshed, and then used as input for a CFD simulation of the airflow in the first generations (levels of airway branching) of the airway tree. Such models are inherently limited to the larger generations of the conducting airways, typically the 6th to 7th generation, due to the limited resolution of CT scans and the high cost of performing a fully resolved 3D CFPD simulation of the entire airway tree. This approach misses large portions of the airways, as well as tissues and structures surrounding the lungs. A particular disadvantage is that estimating the outlet boundary conditions for the distal ends of the simulated part of the airway tree requires two CT scans.Using a CT scan during full inspiration and expiration, image processing techniques are used to calculate lobe expansion across the respiratory cycle. This data is then used to adjust the outflow boundary conditions so that the lobe expansion in the model matches the measured lobe expansion. Furthermore, lobe expansion is assumed to be uniform. Apart from requiring at least two CT scans, the approach described in EP 2 255 843 A1 cannot image structures beyond the lobes. The model does not include smaller distal airways, and neither the alveolar region nor the thorax are considered. The approach is non-predictive in that it cannot extrapolate beyond what was measured with the two CT scans needed to calibrate the model. Another shortcoming of EP 2 255 843 A1 is that expiration cannot be modeled.Deposition statistics can only be estimated assuming that all inhaled particles are deposited. Central to peripheral deposition is approximated by calculating the proportion of particles deposited in the first generations and the total number of particles deposited. Further regional information beyond the lobe level or deposition statistics for higher generations cannot be calculated. Because a second CT is always required for model calibration, the scope of the approach is limited to scenarios where two CT scans are available and precludes application in longitudinal studies where only routine data are available.
[0021] The concept of 3D CFD analysis can be extended beyond the airway generations visible in the CT scan by supplementing airway segmentation with morphological models of higher airway generations (Kronbichler M, Fehn N, Munch P, et al. A next-generation discontinuous Galerkin fluid dynamics solver with application to high-resolution lung airflow simulations. In: Proceedings of the International Conference for High Performance Computing, Networking, Storage and Analysis. SC '21. Association for Computing Machinery; 2021:1-15. doi:10.1145 / 3458817.3476171). However, the three-dimensional resolution of the structure and flow field results in a computational effort that can only be managed in feasibility studies on very large high-performance computing systems. Extending this approach to a 3D CFPD simulation by adding particle transport would further increase the computational effort.
[0022] The method described in WO 2014 / 125059 A1 determines the respiratory state and further aims to optimize its treatment using 3D CFD simulation. It is stated that the disclosed method was able to determine the patient-specific lung dose depending on the patient-specific morphology, aerosol and device properties, and inhalation profiles. However, the modeling approach described in WO 2014 / 125059 A1 is the same as that described in EP 2 255 843 A1, naturally with the same limitations.
[0023] First, the structural model of the lung is limited to geometric information that can be extracted from high-resolution image data. The airway model is thus restricted to the larger airways that can be seen in a high-resolution CT scan. Second, neither the lung tissue nor other structures in the thorax are part of the model described in WO 2014 / 125059 A1. Therefore, the outflow boundary conditions, i.e., the pressures at the bronchiole outlets, for the 3D CFD simulations must be adjusted so that the mass flow matches the mass flow obtained from at least two CT scans. The requirement of two or more volumetric images for model construction represents a major disadvantage in itself, as it requires specialized treatment or study protocols.These requirements expose the patient to a higher radiation dose than when acquiring individual volumetric images, which are used in routine clinical practice. Since exhalation cannot be simulated in WO 2014 / 125059 A1, the method described therein can only approximately determine the effective lung dose by assuming that all particles transported beyond the glottis during inhalation are deposited in the lungs.
[0024] By including only the upper part of the airway tree in the model and omitting the lung tissue and surrounding structures, the lung model described in WO 2014 / 125059 A1 and the achievable spatial resolution of the aerosol deposition pattern are very limited. Information beyond the lobe level cannot be obtained. This limited approach is also described in (De Backer JW, Vos WG, Vinchurkar SC, et al. Validation of Computational Fluid Dynamics in CT-based Airway Models with SPECT / CT. Radiology. 2010; 257(3):854-862. doi:10.1148 / radiol.10100322).
[0025] In summary, the known approaches based on 3D CFD models do not represent the entire airway tree. The airway tree is either truncated before reaching the respiratory zone or only a few selected airways are modeled into the respiratory zone. A 3D CFD simulation of the entire airway tree would incur prohibitive computational costs even for scientific applications using high-performance computers, let alone commercial applications.
[0026] A method for determining a patient-specific ventilation parameter for setting a ventilator with which the patient is to be ventilated is disclosed in WO 2021 / 204931 A1 based on a modeling approach for the fluid and structural mechanics of the lung.
[0027] Neither particle transport in general nor pulmonary drug transport are taken into account.
[0028] None of the aforementioned methods is suitable for assessing the efficacy of pulmonary drug transport throughout the entire lung of a human (or animal). Furthermore, the known methods for predicting or evaluating pulmonary drug transport suffer from low accuracy due to limited resolution and overly simplified modeling approaches. In particular, the effects of inhaler devices on the properties of the generated aerosol to be inhaled are not adequately considered in the state of the art. Summary
[0029] One object of the invention is to overcome at least one problem described in the prior art. In particular, one object of the invention is to evaluate the efficacy of pulmonary drug transport throughout the lung, preferably with increased accuracy and / or in a shorter time.
[0030] A further object of the invention is to provide evaluations of the efficacy of pulmonary drug transport for technical applications, such as the evaluation of the performance of an inhaler device, the evaluation of the efficacy and / or safety of an orally inhaled and / or nasal drug product, in particular a dose of an active ingredient in the drug product, or the evaluation of the efficacy of a drug / device combination product.
[0031] Another object of the invention is to provide a method for developing and / or manufacturing an inhaler device for pulmonary drug delivery with improved efficacy and to provide such an inhaler device.
[0032] Another object of the invention is to provide a method of operating an inhaler device that produces an aerosol with improved efficacy for pulmonary drug transport.
[0033] Another object of the invention is to provide a process for the preparation of an orally inhaled and / or nasal pharmaceutical product having improved efficacy and / or safety and to provide such a pharmaceutical product.
[0034] Another object of the invention is to provide a drug / device combination product comprising an orally inhaled and / or nasal drug product and an inhaler device for administering orally inhaled and / or nasal drug products with improved efficacy and / or safety.
[0035] In particular, the problem is solved by a method for evaluating the efficacy of an aerosol for pulmonary drug delivery, the aerosol comprising aerosol particles containing an orally inhaled and / or nasal drug product, comprising the following steps: - determining at least one aerosol value of at least one aerosol parameter characterising the aerosol, wherein the aerosol is generated in particular by an inhaler device, - Providing a numerical lung model representing the structure of a, preferably human, respiratory system and the transient gas flow in the airways of the respiratory system, at least between the trachea and the lungs, in particular during inspiration and expiration, wherein the numerical lung model is based on a discretized respiratory system structure derived from processed image data representing at least one, preferably human, respiratory system, wherein preferably the discretized respiratory system structure is derived from processed image data of a single tomographic image of each of the at least one respiratory system; - Providing a numerical particle transport and deposition model that represents the transient transport of individual aerosol particles in the gas flow in the airways and the deposition of individual aerosol particles in the respiratory system, - calculating a spatial particle deposition distribution of a plurality of discrete particles deposited in the discretized respiratory system structure based on the at least one aerosol value using the numerical lung model and the numerical particle transport and deposition model; - Calculating at least one efficacy value of an efficacy parameter indicating the efficacy of pulmonary drug transport of the aerosol based on the spatial particle deposition distribution; - Using the efficacy value to automatically assess efficacy for pulmonary drug transport, storing the efficacy value in a storage device, displaying the efficacy value using a display device, and / or transmitting the efficacy value for use in assessing efficacy for pulmonary drug transport.
[0036] The efficacy value may be used or made available (exclusively) for technical applications, e.g., for the (automatic) evaluation of the performance of an inhaler device for pulmonary drug delivery, for the evaluation of the efficacy and / or safety of an orally inhaled and / or nasal drug product, in particular a dose of active ingredient, or for the evaluation of the efficacy of a drug / device combination product for pulmonary drug delivery.
[0037] Further possible technical uses of the efficacy value include: designing and / or manufacturing an inhaler device for pulmonary drug delivery, in particular selecting (setting / implementing) an inhaler design parameter based on the efficacy value; operating an inhaler device for pulmonary drug delivery, in particular setting a device operating parameter of the inhaler device based on the efficacy value; manufacturing an orally inhaled and / or nasal drug product based on the efficacy value; manufacturing or providing a drug / device combination product comprising an orally inhaled and / or nasal drug product and an inhaler device based on the efficacy value.
[0038] Orally inhaled and / or nasal pharmaceutical products within the scope of the invention refer to pharmaceuticals intended to be delivered to the lungs (pulmonary drug delivery). Typically, such pharmaceuticals are administered for inhalation through the mouth, but depending on the circumstances (intentionally or unintentionally), they may also be inhaled (partially) jointly through the mouth and nose, or (intentionally or unintentionally) only through the nose. For example, a patient may use an inhalation mask, e.g., from a nebulizer device, that covers both the mouth and nose to inhale an aerosol of a pharmaceutical, commonly referred to as an orally inhaled pharmaceutical. As such, the invention primarily relates to pharmaceuticals that are (exclusively) inhaled orally.Accordingly, orally inhaled and / or nasal pharmaceutical products within the meaning of the invention do not include pharmaceuticals that are administered for inhalation through the nose and are intended to be transported (predominantly) (only) into the nose (but not into the lungs), in particular to be absorbed by the nasal mucosa, such as nasal sprays.
[0039] Furthermore, orally inhaled and / or nasal medicinal products can be inhaled actively, i.e., through spontaneous breathing of an individual (a healthy person or a patient), or passively, i.e., through artificial ventilation of a patient, in particular through artificial (mechanical) ventilation. Any mixed form of active and passive breathing, such as assisted spontaneous breathing, is included. Accordingly, the term "inhaler device" refers to any device capable of delivering an aerosol for pulmonary drug delivery, regardless of whether the drug is delivered to the lungs by active or passive inhalation.
[0040] The efficacy of pulmonary drug transport can be assessed, among other things, for drugs administered to treat lung diseases such as asthma, chronic obstructive pulmonary disease (COPD), or idiopathic pulmonary fibrosis (IPF), particularly for the treatment of (local) tissue-level pathologies such as emphysema or fibrosis, especially inflammation of the lung tissue. Other drugs can be administered to treat pulmonary arterial hypertension (PAH), respiratory distress syndrome (IBS), or infectious diseases. The efficacy of pulmonary drug transport can also be assessed for cannabis as a drug.
[0041] Active ingredients in orally inhaled and / or nasal drug products may include, among others: inhaled bronchodilators for the treatment of obstructive airway diseases such as asthma and COPD, anti-inflammatory products including glucocorticoids for the treatment of inflammation of lung tissue, anti-infectives for the treatment of infectious diseases, recombinant human deoxyribonuclease (rhDNase) for the treatment of cystic fibrosis, mannitol for the treatment of bronchiectasis and cystic fibrosis, prostacyclins for the treatment of pulmonary arterial hypertension (PAH), or lung surfactant for the treatment of respiratory distress syndrome (IBS). Drug products may also be intended for systemic therapies not limited to purely respiratory diseases, containing active ingredients such as nicotine or loxapine. THC may also be an active ingredient, particularly in orally inhaled drug products containing or consisting of cannabis.
[0042] An aerosol is a mixture of solid and / or liquid particles (suspended particles) and a carrier gas. The carrier gas can be or contain air and / or another gas, in particular oxygen and / or helium. A carrier gas can be a mixture of different gases, in particular atmospheric oxygen and / or helium. An aerosol with solid particles can be produced from a powder. An aerosol with liquid particles in the form of droplets can be produced by atomizing a liquid.
[0043] An aerosol parameter can be understood as a parameter that characterises an aerosol, preferably by specifying one or more physical properties of an aerosol, in particular the physical properties of the particles or carrier gas that the aerosol contains, or of the aerosol (as a whole).
[0044] Evaluating efficacy for pulmonary drug transport may mean predicting, monitoring, and / or evaluating the efficacy of an orally inhaled and / or nasal drug that could theoretically be administered to a (human or animal) body in the future, or that has been administered to a (human or animal) body in the past. However, the methods of the invention are not therapeutic methods for treating the human or animal body. A step of actually administering a drug to the human or animal body is not included in the described methods.
[0045] An efficacy parameter indicating the efficacy of pulmonary drug transport of an aerosol may indicate how well the aerosol is suited for pulmonary drug transport, in particular with regard to the amount of aerosol particles transported to the lungs (deposited in the lungs) and / or the area (location, zone, and / or airway generation) in which the aerosol particles deposit in the lungs (spatial particle deposition distribution), in particular an active drug ingredient contained in the aerosol particles. In particular, the efficacy parameter may indicate an amount and / or ratio of a drug (active ingredient) delivered to at least one, preferably specific, area(s) in the lungs, such as location(s) in the airways, left / right lung, lung lobes and / or airway generation(s), etc.In addition, the efficacy parameter may indicate an amount and / or ratio of a drug (active ingredient) that passes through the lungs into the bloodstream and / or lung tissue.
[0046] The processed image data representing at least one respiratory system are preferably obtained from an imaging (tomographic) method applied to a (human or animal) respiratory system, in particular to the lungs, in a (real) body of a healthy (human or animal) individual or a (human or animal) patient, in particular a patient with a lung disease. Preferably, the discretized respiratory system structure is derived from processed image data of (only) a single, preferably tomographic image of each of the at least one (real) respiratory system. In particular, the single (tomographic) image represents (only) one state (inhaled, exhaled, or in between) of the respiratory system, preferably at (only) one point in time.The processed image data can (exactly) represent a (real) respiratory system or an (averaged) plurality of (real) respiratory systems, preferably from different individuals. The processed image data can represent a (single) real respiratory system or a (single) virtual (averaged and / or modified) respiratory system. The processed image data can represent (parts of a) healthy and / or (parts of a) pathological respiratory system.
[0047] Transient (time-dependent) gas flow in the airways refers specifically to the (laminar and / or turbulent) flow of gas (air and / or carrier gas) in the airways during inhalation and / or exhalation. Particle transport refers specifically to the (passive) transport (movement) of a (solid or liquid) aerosol particle in the gas flow, particularly due to the forces of the gas flow acting on the particle.
[0048] A drug / device combination product is understood to mean a drug that includes both a drug product, in particular containing a specific dose of a drug, and a medical device for administering the drug. For the purposes of this disclosure, a drug / device combination product for pulmonary drug delivery includes an orally inhaled and / or nasal drug product and an inhaler device for administering the orally inhaled and / or nasal drug product. In particular, the efficacy of the drug / device combination product for pulmonary drug delivery in combination depends on both the efficacy (and / or safety) of the drug product and the performance of the inhaler device.
[0049] At least some, preferably all, steps can be performed with the aid of a computer (computer-implemented method). In particular, method steps that include calculations can be executed by at least one processor. In particular, method steps that include calculated models can use at least one storage medium and / or a database that provides the calculation model.
[0050] The method has the advantage of allowing the effectiveness of pulmonary drug transport across the (whole) lung to be assessed. This is achieved by considering the transport and deposition of individual aerosol particles in the (whole) lung during inspiration and expiration. Furthermore, by using a single (tomographic) image of an individual's (patient's) respiratory system, the radiation dose to which the individual is exposed is reduced. This comprehensive approach leads to a higher accuracy of the obtained spatial particle deposition distribution. This enables a more accurate and reliable prediction and / or evaluation of drug transport into the lung, in particular the targeted drug transport to specific areas of the lung.Local aerosol deposition and quantification of the transported (delivered) drug dose at any desired site of action in the (whole) lung can be accurately assessed and / or predicted, especially for a specific individual (patient specific).
[0051] In embodiments of the method, the at least one aerosol parameter specifies one or more of the following parameters: a particle size, preferably an average particle size, a particle size distribution, a particle density, a particle shape, preferably an average particle shape, an aerosol flow, which is preferably time-dependent, in particular relative to a respiratory cycle, a flow velocity of the aerosol, a type of carrier gas, and a pressure of a carrier gas of the aerosol. An aerosol parameter can be a setting from a plurality of individual aerosol parameters that collectively characterize the aerosol.
[0052] Normally, homogeneous aerosol parameters (particle size, particle density, particle volume, particle shape, particle velocity, etc.) within an aerosol are technically impossible to achieve in physical reality. In practice, aerosol parameters (particle size, etc.) are generally subject to a distribution (size distribution, etc., usually a log-normal distribution). Therefore, an aerosol value of an aerosol parameter (particle size, etc.) for an aerosol particle can be understood as the value of those particles in the distribution (size distribution, etc.) with the highest probability or a (narrow) range of the distribution around the value with the highest probability.
[0053] The particle size can be understood as an equivalent particle size, e.g. of a droplet (liquid) or of a solid particle, e.g. from a powder. The particle size can be a (mean) particle diameter, in particular of (spherical) droplets, or of the equivalent diameters of solid particles of different shapes, in particular of a powder. The particle size distribution is preferably a log-normal distribution, which is preferably described by the mass median of the aerodynamic diameter and / or the geometric standard deviation. A log-normal distribution can be understood as a continuous probability distribution of a random variable (e.g. the particle diameter) whose logarithm is normally distributed. Particle sizes for aerosols generated, for example, by nebulizers can be determined according to DIN EN 13544-1.Particle density can be the (averaged) number of particles contained per aerosol volume. Particle size (particle size distribution) and particle density are among the most important parameters that determine particle transport in the lungs.
[0054] An aerosol flow can be an aerosol mass flow or an aerosol volume flow, preferably time-dependent relative to a (human) respiratory cycle. The pressure of the carrier gas as an aerosol parameter can be time-dependent. An aerosol flow velocity or a particle (mean) velocity can be defined at a specific point along the aerosol flow path, preferably at the inlet of the trachea and / or at the outlet of an inhaler device.
[0055] A carrier gas preferably contains air, helium, oxygen, or a mixture thereof. An aerosol parameter that characterizes the (carrier gas of an) aerosol can be the density, composition, and / or molecular weight of the carrier gas. The type of carrier gas in the aerosol affects particle transport in the lungs, particularly the relationship between the density of the carrier gas and the density of the aerosol particles.
[0056] In addition to the aerosol parameters mentioned above, further aerosol parameters may include, but are not limited to, particle (surface) charge, particle hydrophobicity, and / or particle binding affinity. An aerosol parameter may indicate the amount of drug substance contained in a particle, in particular, the amount of drug substance per particle volume.
[0057] In some embodiments of the method, the at least one aerosol value is determined by - Measuring the aerosol value, - Obtaining the aerosol value from a database containing data indicating the physical properties of the aerosol, - Obtaining or deriving the aerosol value from the specification data of an inhaler device, - Calculating the aerosol value based on analytical relationships of the physical properties of the aerosol, and / or - Calculating the aerosol value, in particular as a result of a numerical simulation of a generation process and / or a flow of the aerosol, in particular in an inhaler device, preferably using a numerical inhaler device model.
[0058] Aerosol values of aerosol parameters can be measured (in experiments), obtained (from a database), and / or calculated (analytically or in numerical simulations) prior to performing the procedure for evaluating the efficacy of the aerosol for pulmonary drug delivery, possibly stored (buffered), and subsequently used as input aerosol values for the procedure. The data obtained from a database can be (previously) measured or previously calculated (precalculated). The determined aerosol values can be a combination of measured, calculated, and otherwise obtained aerosol values.
[0059] In one embodiment, the method further comprises a step of determining at least one respiratory value of a respiratory parameter that characterizes the breathing of the respiratory system, in particular spontaneous breathing, assisted spontaneous breathing and / or artificial ventilation, wherein the respiratory value defines a boundary condition of the numerical lung model. Preferably, the respiratory parameter is one or more of - a pressure difference, preferably time-dependent, preferably between a pleural space and the trachea, - a preferably time-dependent inhalation and / or exhalation gas flow, - a minimum and / or maximum value of the lung pressure and a value of the respiratory cycle frequency, in particular for pressure-controlled artificial ventilation, and - an inhalation and / or exhalation gas volume, in particular for volume-controlled artificial ventilation.
[0060] A respiratory parameter can be a respiratory rate that indicates individual (patient-specific) respiration over time, such as an (individual) gas flow during inhalation and / or exhalation, an (individual) lung volume, or an (individual) lung pressure over time, preferably over at least one (complete) respiratory cycle (respiratory time interval across inhalation and exhalation). A respiratory rate can refer to spontaneous respiration, assisted spontaneous respiration, and / or artificial ventilation. The respiratory rate, in particular the (sequence of) respiratory value(s), can be used to calibrate the numerical lung model, in particular to determine (all) necessary boundary conditions for the numerical lung model. Preferably, the (measured) respiratory rate is compared (synchronized) with the lung state in which the tomographic image was taken (e.g.,full inhalation or full exhalation).
[0061] Respiratory value(s), in particular a sequence of respiratory values representing a (discrete) respiratory curve, can be derived (optionally using additional calculations and / or parameters) from a measured individual (patient-specific), time-dependent respiratory curve, preferably over a complete respiratory cycle. A respiratory value can be derived based on a measured, preferably time-dependent, inspiratory and / or expiratory gas flow (respiratory cycle: inhalation and exhalation) and / or a lung volume of an individual (patient). One or more respiratory value(s) of a respiratory parameter can be determined or derived based on at least one measurement, e.g., with a spirometer.
[0062] In a preferred embodiment, a respiration value is derived based on a time-dependent inhalation and exhalation gas flow (v(t) [ml / s]) measured for the individual (the patient) to whom the (tomographic image of the) respiratory system belongs. Preferably, the measurement (e.g., measurement of a respiration rate v(t)) is performed using a spirometer. In general, a spirometer is a known medical device for measuring the volume of air (gas) inhaled and exhaled by the lungs. A respiration value may be a tidal lung volume (e.g., in liters [l] or milliliters [ml]), which indicates a volume difference (ΔV [ml]) between a (fully) exhaled and a (fully) inspired state of the lungs (i.e., tidal volume [ml]). A (tidal) lung volume may be derived from a measured inhalation and / or exhalation gas flow, e.g., by integration over time.The respiration value can be determined or derived based on previously recorded (pre-recorded) measured respiration data representing an inhaled and / or exhaled gas flow, in particular over a (complete) respiratory cycle, of an individual (patient-specific measured respiration data). In an alternative embodiment, a respiration value could be derived based on at least one measured lung pressure (pressure curve p(t)), in particular based on a minimum lung pressure value (fully exhaled lung state) and a maximum lung pressure value (fully inspired lung state). A respiration value can also be derived based on a combination of measured gas volume flow(s) and measured lung pressure(s).
[0063] A pressure difference, particularly between a pleural space and the trachea, can be derived (calculated) based on measured values, particularly based on a measured time-dependent inspiratory and / or expiratory gas flow and / or lung volume, and specified as a boundary condition for the lung model. A derived (calculated) pressure difference can correspond to a measured gas flow. A respiratory value characterizing artificial ventilation can refer to pressure-controlled (applied pressure-time curve) or volume-controlled (applied flow-time curve) artificial ventilation.
[0064] Based on the respiration value(s), in particular the (time-dependent) boundary conditions derived therefrom, the numerical lung model is preferably able to represent the gas flow in the airways both during inhalation and during exhalation, in particular based on (only) a single (tomographic) image of a respiratory system in combination with at least one, preferably measured, respiration value characterizing the respiration of the respiratory system.
[0065] In one embodiment of the method, the discretized respiratory system structure is based on a spatial segmentation of the structure of the, preferably conductive, airways of the respiratory system into a plurality of discrete, preferably spatially three-dimensional, preferably tubular, airway segments and preferably a temporal discretization of time steps. Preferably, the gas flow velocity within at least some of the airway segments is constant for each time step.
[0066] A (3D) airway segment preferably comprises a (tubular) airway wall (hollow cylinder), preferably straight in the axial direction and / or with an axisymmetric cross-section. The cross-section within each airway segment can be constant (straight-cylindrical airway segment) or decreasing in the downstream (inhaling) direction (conical airway segment). Preferably, the discretized respiratory system structure represents the (entire) airway tree of the (human) lung, preferably comprising at least the (leading) airways downstream of the trachea, optionally also the regions of the mouth, pharynx, and / or larynx. Such a discretized respiratory system structure adequately depicts the anatomical structure of the airways of the (human) lung. In medical literature, 23 airways of the human lung are usually distinguished. Within the leading airways, each generation corresponds to a level of airway branching (i.e.n levels of airway branching correspond to n+1 airway generations).
[0067] The gas flow velocity can be modeled as a three-dimensional (3D flow) discretized velocity field in some airway segments, preferably in lower airway generations (e.g., in generations 0, 0-1, or 0-2), and as a reduced-dimensional, preferably zero-dimensional (0D flow, scalar velocity value) discretized velocity field in other airway segments, preferably in higher airway generations (e.g., in generations above 0, 1, or 2). It is possible to calculate a (computationally intensive) 3D CFD simulation for lower (the first few) airway generations and a (computationally less expensive) 0D simulation for higher airway generations (up to the last structurally resolved airway generation). Preferably, the gas flow velocity is constant for each time step in all airway segments of the discretized respiratory system structure.Modeling (adjusting) the gas flow velocity within the airway segments when calculating the spatial particle deposition distribution leads to a reduction in computational effort.
[0068] In one embodiment of the method, the numerical lung model represents the structure of at least six, preferably at least eight, more preferably at least ten, even more preferably at least twelve generations of the airways. Preferably, the numerical lung model further represents the mouth, the pharynx and / or the larynx and preferably further represents the alveoli of the lung. Preferably, the numerical lung model represents the transient gas flow in the airways between the mouth and the lung, in particular between the mouth and the alveoli of the lung. Preferably, the numerical lung model represents a closed volume of the airways and / or the numerical lung model represents the structural elasticity of the airways, in particular the structural elasticity of the airway walls and / or the structural elasticity of the lung tissue.Preferably, the numerical lung model additionally represents the diaphragm and / or the thorax (rib cage), in particular by applying a preferably volume-dependent force to the (discretized respiratory system structure of the) lung as a boundary condition.
[0069] Since the numerical lung model can represent the resistance (mechanical reaction force due to elasticity) of the airway walls and / or lung tissue and resolves and / or models the airways of the (entire) lung, i.e. the discretized airways comprise a closed volume in which aerosol particles are transported, it also (automatically) takes into account exhalation, in particular the exhalation of previously inhaled aerosol particles.
[0070] However, state-of-the-art numerical lung models are unable to account for the exhalation of aerosol particles. In particular, the numerical lung model in EP 2 255 843 A1 does not include the smaller distal airways and the alveolar region due to the reduction in airway structural resolution at a relatively low airway generation. Therefore, the lung model represents an open airway volume (open at the outflow in the direction of inhalation), meaning that the exhalation of previously inhaled aerosol particles cannot be accounted for in EP 2 255 843 A1. Inhaled particles that reach the last result generation of the airways leave the computational domain and are "lost."
[0071] In one embodiment of the method, the numerical lung model is based on a discretized individual respiratory system structure derived from processed image data representing an individual respiratory system, preferably that of a healthy individual or a patient suffering from a lung disease. A numerical lung model can represent an individual (patient-specific) respiratory system of a real individual (patient). Preferably, the numerical lung model is based on a discretized patient-specific respiratory system structure derived from processed image data and representing an individual pathological respiratory system of a patient suffering from a lung disease. Such a lung model can be used to evaluate the effectiveness of pulmonary drug transport for that individual patient.
[0072] In another embodiment of the method, the numerical lung model is based on a discretized averaged respiratory system structure derived from preferably averaged processed image data representing an average of several, preferably individual respiratory systems, preferably of at least one healthy individual and / or at least one patient suffering from a lung disease. Processed image data of a plurality of individual (tomographic) images of different respiratory systems, i.e., of different individual persons, can be averaged, preferably using an image data averaging algorithm, to obtain averaged processed image data. Based on the averaged processed image data, a discretized averaged respiratory system structure can then be derived, representing a (virtual) averaged respiratory system.
[0073] If the numerical lung model represents an averaged healthy lung (derived from a multitude of images of different healthy lungs), the model can be used to evaluate the (potential) efficacy of pulmonary drug transport in a comparative study of a normal (average) healthy lung. If the numerical lung model represents an averaged pathological lung (derived from a multitude of images of different pathological lungs), the model can be used to evaluate the (potential) efficacy of pulmonary drug transport in a representative study of a typical (average) pathological lung.Such studies could significantly accelerate and / or reduce the costs of medical approval procedures for orally inhaled and / or nasal drug products, for example by applying the procedure to a digital cohort of individuals represented by appropriate numerical lung models.
[0074] In one embodiment of the method, the numerical lung model is based on a discretized respiratory system structure derived from processed image data representing at least one healthy respiratory system and at least one predetermined pathological image data pattern representing a preferably local pathological change in at least one zone of the respiratory system caused by a lung disease. The processed image data can represent (parts of) at least one healthy and / or (parts of) at least one pathological respiratory system. In particular, individual or averaged processed image data can be modified by an image data modification algorithm using at least one predetermined pathological image data pattern.
[0075] A predetermined pathological image data pattern can represent typical pathological changes in a (tomographic) image of a normal (healthy) lung caused by a specific lung disease and recognizable as a pathological pattern in (tomographic) images. Such pathological changes can be local changes in the airways (altered airway diameter) or lung tissue (pathological tissue) that can typically be observed in (tomographic) images of patients with a specific lung disease.
[0076] A pathological image data pattern can be an instance (a data set) of (tomographic) image data representing a (local) section of a (tomographic) image that (locally) exhibits a pathological pattern. An algorithm for modifying image data can modify image data, in particular averaged processed image data, using the pathological image data pattern, e.g., by adding the pathological image data pattern as a data subset and / or by replacing a portion of the averaged processed image data with the pathological image data pattern (data subset).A predetermined pathological image data pattern can be obtained from a database in which a plurality of different typical pathological image data patterns are stored, preferably collected for different types of patients (lung disease, individual medical history, age, gender, habits, lung volume, previous treatments received, other non-lung-specific medications, etc.).
[0077] Alternatively, a pathological image data sample can be an instance (a dataset) of structural data representing a (pathological portion of a) discretized respiratory system structure extracted (as a data subset) from a discretized, averaged respiratory system structure derived from averaged, processed image data representing an average of multiple respiratory systems from multiple patients with a specific lung disease. Thus, instead of modifying the (averaged) image data and deriving a (locally) modified discretized respiratory system structure from it, the derived discretized respiratory system structure can also be (locally) modified according to the (local) pathological change.
[0078] If the numerical lung model represents an individual healthy lung and is modified based on a lung model of an average pathological lung, the model can be used to evaluate the (potential) efficacy of pulmonary drug transport for a specific (healthy) individual in the event that that individual develops the corresponding lung disease. If the numerical lung model represents an averaged individual healthy lung and is modified based on a lung model of an average pathological lung, the model can be used to evaluate the (potential) efficacy of pulmonary drug transport in the event that a generally healthy individual develops the corresponding lung disease.Such studies could significantly accelerate and / or reduce the costs of medical approval procedures for orally inhaled and / or nasal drug products, for example by applying the procedure to a digital cohort of individuals represented by appropriate numerical lung models.
[0079] In one embodiment of the method, the numerical particle transport and deposition model implements a Lagrangian approach for tracking individual discrete particles transported in the gas flow, in particular based on the modeling of at least one physical force acting on each individual discrete particle, in particular a gravitational force, a drag force, a buoyancy force, and / or a Brownian motion force. In particular, the unsteady (dynamic) motion and deposition of each individual discrete particle is tracked individually, in particular within each airway segment, preferably throughout inspiration and expiration. The implemented Lagrangian approach is preferably a one-way coupled approach, meaning that the effect of the transient gas flow in the airways on the particles is taken into account, but not vice versa.In particular, the direction of the gravitational force in the numerical particle transport and deposition model is adjusted depending on the spatial, preferably vertical or horizontal, orientation of the respiratory system represented by the processed image data. A spatial orientation of the respiratory system preferably corresponds to an upright sitting (vertical) or lying (horizontal) position of an individual, in particular a patient. To evaluate the effects on pulmonary drug transport during upright inhalation (and exhalation) compared to inhalation (and exhalation) while lying down, different directions of gravity can be used. The flow resistance force is preferably calculated based on the density and / or viscosity of a predetermined type of carrier gas, preferably air, helium, or oxygen, of the aerosol.The buoyancy force is preferably calculated based on the different densities of the aerosol particle and the carrier gas. The Brownian motion force is preferably calculated based on randomly generated velocity fluctuations, especially when a discrete particle is located in an alveolar zone of the discretized respiratory system structure. The implemented Lagrangian approach enables the tracking of individual aerosol particles at any location throughout the airway tree and lung tissue throughout inspiration and expiration. This allows for more accurate, especially local, spatial particle deposition distributions to be calculated, taking into account (all) individual particles within the computational domain.
[0080] In one embodiment of the method, a discretized particle transport velocity field, in particular within a spatially three-dimensional airway segment, has a higher spatial dimension than a discretized gas flow velocity field, in particular within the spatially three-dimensional airway segment, at least within a part of the discretized respiratory system structure, preferably within airway segments belonging to at least a second, preferably at least a third generation of the airways represented by the numerical lung model.Preferably, a three-dimensional (3D flow) discretized particle transport velocity field within each spatially three-dimensional airway segment is calculated (reconstructed) based on a constant (0D flow) discretized gas flow velocity within each spatially three-dimensional airway segment, at least within a portion of the discretized respiratory system structure, preferably throughout the entire discretized respiratory system. In particular, the discretized particle transport velocity field is used as input (one-way coupled approach) for the numerical particle transport and deposition model. The discretized gas flow velocity field can be obtained from the numerical lung model.The use of a reduced-dimensional approach for the gas velocity field reduces computational costs and, in particular, saves computational resources for improving the spatial resolution of the airway tree. Overall, tracking individual particles across the entire elementary range becomes possible while still sufficiently resolving the transient gas flow.
[0081] In one embodiment of the method, the numerical particle transport and deposition model tracks individual discrete particles within a spatially three-dimensional airway segment by using a, preferably three-dimensional, particle transport velocity vector as the velocity of a particle. The particle transport velocity vector is preferably calculated based on a predetermined three-dimensional velocity profile across the cross-section of the airway segment and a preferably constant gas flow velocity obtained from the numerical lung model for the airway segment. The gas velocity field is preferably (spatially) constant within (each) airway segment and, in particular, discontinuous between adjacent airway segments.Preferably, a normalized velocity profile corresponding to a laminar flow (Poiseuille flow, in particular parabolic) or a turbulent flow, in particular taking into account the turbulent boundary layer at the airway walls, is multiplied by the (constant) gas flow.
[0082] In one embodiment, the method further comprises a step of inserting individual discrete particles into the gas flow in the respiratory tract, comprising - Assigning an insertion position in an inflow cross-section of the discretized respiratory system structure, preferably in an inflow cross-section of the trachea, to each individual discrete particle, and / or - Assigning a deployment time for each individual discrete particle based on a particular aerosol flow, which is preferably time-dependent, in particular relative to a breathing cycle.
[0083] The insertion of individual discrete particles preferably further comprises assigning insertion velocity, insertion acceleration, particle density, particle size, particle shape, particle mass, and drag coefficient to each individual discrete particle. The insertion position is preferably determined based on - Obtaining or deriving a statistical spatial distribution of aerosol particles in the aerosol, preferably based on measured, pre-calculated and / or randomly generated aerosol particle distribution data, - Calculating a particle location of the individual discrete particle in a numerical simulation of a generation process and / or a flow of the aerosol, in particular in an inhaler device, preferably using a numerical inhaler device model, and / or - Measuring the spatial distribution of aerosol particles in the aerosol.
[0084] The onset of individual discrete particles can be based on the condition of a time-averaged uniform spatial distribution across an inflow cross-section of the inflow (the trachea). An onset time is preferably an onset time step, which is preferably derived from a predetermined onset frequency or obtained from a predetermined sequence of onset time steps. A calculated onset position can be the result of a particle position as output of a 3D CFPD simulation of at least one generation of the (larger, i.e., upper) airways, preferably the trachea.In particular, the particle position of an individual discrete particle resulting from a 3D CFPD simulation of a first (lower) generation of airways can be assigned as the insertion position in an inflow cross-section of a second, preferably next, (higher) generation of the (still quite large) airways of the discretized respiratory system structure. In particular, a particle location resulting from a 3D CFPD simulation of an upper section of the (larger) airways is used as input for a 0D particle simulation in the (remaining) lower section of the (smaller) airways.
[0085] In one embodiment of the method, the numerical particle transport and deposition model determines the flow path of an individual discrete particle across an airway branch, preferably during exhalation and / or inhalation, by assigning the particle to a downstream airway segment based on the evaluation of at least one geometric branching criterion. A geometric branching criterion is preferably based on a geometric relationship between an outflow cross-section of an upstream airway segment and an inflow cross-section of a downstream airway segment. Preferably, a geometric branching criterion is evaluated based on a position of the particle, in particular a radial and / or circumferential position in an outflow cross-section of an upstream airway segment.
[0086] In particular, an airway branch comprises an upstream airway segment and two downstream airway segments. In the inspiratory flow direction of a respiratory system, an airway branch comprises an upstream airway segment and two downstream airway segments branching off from it. In the exhalation flow direction of a respiratory system, an airway branch comprises two upstream airway segments that flow into a downstream airway segment.
[0087] The evaluation of a (purely) geometric branching criterion requires little computation time. Especially during exhalation (reverse branching transfer), the use of a geometric branching criterion can be sufficient, since the flow path of the particles leads via a branch into a common downstream airway segment. Based on the geometric criterion, only the radial and circumferential position of the particles needs to be determined.
[0088] In one embodiment of the method, the numerical particle transport and deposition model determines the flow path of an individual discrete particle through an airway branch, preferably during inhalation, using at least one pre-calculated airway branch scenario. Preferably, each pre-calculated airway branch scenario is based on an evaluation of at least one previously performed higher-dimensional, preferably three-dimensional, simulation of particle transport in the gas flow across an airway branch. The at least one pre-calculated airway branch scenario is preferably obtained from an airway branch library, in which a plurality of different pre-calculated airway branch scenarios are preferably stored.
[0089] A pre-calculated airway branching scenario can assign a particle in an upstream airway segment of an airway branch to one of two downstream airway segments of the airway branch, in particular to a specific cross-sectional position in an inflow cross-section of the downstream airway segment. A pre-calculated expiratory airway branching scenario can assign a discrete particle in one of two upstream airway segments of an airway branch to a downstream airway segment of the airway branch and assigns the discrete particle a specific cross-sectional location in an inflow cross-section of the downstream airway segment.
[0090] The method may comprise a step of interpolation between more than one, preferably two, pre-calculated airway branching scenarios. In particular, the flow path of an individual discrete particle via an airway branch with a specific branching geometry, preferably a specific branching angle, may be derived from an interpolation of at least two (preferably two) pre-calculated airway branching scenarios with different branching geometries, preferably different branching angles. The interpolation of pre-calculated airway branching scenarios is preferably based on an interpolation of at least two (preferably two) branching geometry parameters and a corresponding interpolation of at least two (preferably two) cross-sectional locations in an inflow cross-section of the downstream airway segment. A pre-calculated branching scenario is preferably used as an alternative to a (purely) geometric branching criterion, but can also be used in addition. Pre-calculated branching scenarios can be based on relatively complex pre-calculated three-dimensional flow / particle transport simulations (3D-CFPD: 3D Computational Fluid and Particle Dynamics) over branches with high spatial and temporal resolution, preferably considering turbulent flows, especially depending on a specific (type of) branching geometry. The use of pre-calculated branching scenarios enables the accurate calculation of a spatial particle deposition distribution, even though (only) a gas flow velocity field in reduced dimension (0D flow) is used.The flow path of an individual particle across a branch, especially during inhalation, can be accurately predicted, particularly with similar accuracy as in a 3D CFD simulation while reducing computational effort.
[0091] In one embodiment, preferably the preceding embodiment, a pre-calculated airway branching scenario predicts the transport of a discrete particle across an airway branch based on a classified type of branching geometry of the airway branch and / or based on a location of the discrete particle in an upstream airway segment, preferably in a radial sector and / or in a circumferential sector of the upstream airway segment. Preferably, a pre-calculated airway branching scenario assigns the discrete particle a cross-sectional position in an inflow cross-section of a downstream airway segment.
[0092] In one embodiment, preferably one of the two preceding embodiments, to determine the flow path of an individual discrete particle across a particular airway branch, a suitable pre-calculated airway branch scenario is selected, preferably from an airway branch library, based on at least one or more of the following: a preferably radial and / or circumferential position of the discrete particle in an upstream airway segment, at least one geometric parameter indicating the branching geometry of the airway branch, a particle size of the discrete particle, a particle density in the zone of the airway branch, and a particle velocity upstream of the airway branch.
[0093] The geometric parameter is preferably one or more of the following parameters: a branching angle between two downstream airway segments, a rotational orientation of one or more downstream segments about a central axis of an upstream airway segment and / or a flow deviation angle between a central axis of an upstream airway segment and a central axis between two downstream airway segments.
[0094] In one embodiment of the method, the numerical particle transport and deposition model determines the deposition of a discrete particle based on the evaluation of at least one deposition criterion, wherein the evaluation of the deposition criterion preferably comprises at least one or more of the following criteria: evaluating whether a calculated distance value of the discrete particle to an airway wall of an airway segment is equal to or less than a predetermined deposition distance, evaluating whether a calculated particle velocity of the discrete particle is equal to or less than a predetermined minimum velocity, and / or evaluating whether a calculated angle of impact between the flow path of the discrete particle and an airway wall of an airway segment exceeds a predetermined minimum angle, which is preferably at least 45°, preferably at least 60%, preferably at least 75°.Optionally, a deposition criterion depends on the shape of the discrete particle and / or the attractive forces between the discrete particle and the airway segment. Two or more of the described deposition criteria can be combined. The deposition criterion is used to determine whether, where, and when an individual particle will deposit within an airway segment. The calculation of the (all) locations of (all) deposited particles based on the evaluation of at least one deposition criterion forms the basis for calculating the spatial particle deposition distribution.
[0095] In one embodiment of the method, the step of determining at least one aerosol value uses a numerical inhaler device model that represents a generation process and / or a flow of an aerosol in an inhaler device. The inhaler device preferably comprises a (dry powder) inhaler device, a metered-dose inhaler device, a soft-mist inhaler device, and / or an inhaler device that has a breathing tube system.
[0096] The numerical inhaler device model represents in particular one or more of the following elements - a particle size distribution of the aerosol, - a particle density of the aerosol, - a pressure of the carrier gas of the aerosol, preferably at the outlet from a mouthpiece and / or a ventilation tube system of the inhaler device, preferably time-dependent relative to a breathing cycle, - an aerosol flow, preferably at the outlet from a mouthpiece and / or a breathing tube system of the inhaler device, preferably time-dependent relative to a breathing cycle, and - a flow velocity of the aerosol, preferably upon exit from a mouthpiece and / or a breathing circuit of the inhaler device, preferably time-dependent relative to a breathing cycle, preferably depending on at least one or more selected device design parameters, a set device operating parameter, and a breathing value of a breathing parameter that influences the generation process and / or the flow of the aerosol in the inhaler device. The numerical inhaler device model can be based on a CFD (Computational Fluid Dynamics) simulation, preferably 3D CFD, based on a structural model of the geometry (of parts) of the inhaler device, preferably obtained from a CAD (Computer Aided Design) model.A device design parameter may characterize a dimension of the inhaler device, in particular (a part of) a flow area (of a component) of the inhaler device.
[0097] A respiratory value of a respiratory parameter may be a boundary condition for the numerical inhaler device model, preferably a gas flow for inhalation and / or a suction pressure for inhalation, which is specified at an outlet of the numerical inhaler device model, preferably time-dependent relative to a respiratory cycle.
[0098] In one embodiment of the method, the step of determining at least one aerosol value uses a numerical inhaler device model that represents the flow of an aerosol in an inhaler device. The numerical inhaler device model preferably represents at least one component of the inhaler device, which is characterized by at least one device design parameter. The device design parameter is preferably indicative of one or more of - a shape of the mouthpiece and / or the breathing circuit of the inhaler device, - a diameter and / or shape of a nozzle of the inhaler device, - a flow channel geometry from an outlet of an aerosol generation and / or aerosol storage chamber to an outlet, preferably of a mouthpiece and / or a ventilation hose system, of the inhaler device, and - a volume and / or geometry of a container containing a preferably liquid, orally inhaled and / or nasal medicinal product.
[0099] A device operating parameter may specify an (adjustable) setting of the inhaler device. An inhaler operating parameter is, in particular, selected from one or more of the following parameters: - a, preferably time-dependent, pressure in a canister containing an orally inhaled pharmaceutical product, preferably a canister adapted to be received in a metered-dose inhaler device; - a mass and / or volume flow of a carrier gas supplied to the inhaler device; - the jet velocity of a jet of a liquid orally inhaled pharmaceutical product impinging on a nebulising device such as a deflection plate, preferably a soft-mist inhaler device; - a vibration frequency of a nebuliser, preferably a soft mist inhaler; and - a rotation speed and / or a groove geometry of a nebulizing device.
[0100] Preferably, at least one device design parameter, one breathing parameter, and / or one device operating parameter influences the aerosol generation process and / or flow in the inhaler device and is represented by the numerical inhaler device model. The specific parameter(s) represented by the numerical inhaler device model depend(s) on the inhaler device used, e.g., a dry powder inhaler device, a metered-dose inhaler device, a soft-mist inhaler device, and / or an inhaler device having a breathing circuit.
[0101] In one embodiment of the method, the efficacy parameter specifies one or more of the following parameters: a, preferably local, effective dose (effective dose); a, preferably local, density of the deposited aerosol particles; and a, preferably local, concentration of an active ingredient of the orally inhaled and / or nasal pharmaceutical product. An effective dose may be the amount of active ingredient transported into or delivered to the lungs. A locally effective dose may be an amount of active ingredient transported to a specific area of the respiratory system, in particular an area in the lungs, such as a specific location(s) (zone) in the airways or lung tissue, the left or right lung, the lung lobes, and / or the airway generation(s).
[0102] A (locally) effective dose or concentration of an active ingredient can be determined at least based on the calculated spatial particle deposition distribution and a predetermined dose (concentration and / or amount) of the active ingredient contained in (each) deposited particle. Based on the calculated spatial particle deposition distribution, a density of the deposited aerosol particles can be determined, in particular as the number of deposited aerosol particles per (lung) volume and / or (internal) airway surface. In particular, particles that were inhaled but later exhaled are not part of the spatial particle deposition distribution.
[0103] The efficacy parameter, in particular a (locally) effective dose, can be an equivalent efficacy parameter, in particular an equivalent (locally) effective dose, of a similar (generic) pharmaceutical product, in particular in relation to an original pharmaceutical product. The described method for assessing efficacy for pulmonary drug transport can be used to assess whether a similar, in particular generic, pharmaceutical product, preferably containing the same active ingredient, has the same efficacy for pulmonary drug transport as the original pharmaceutical product. Thus, the described method can be used to accelerate and / or simplify medical administration processes.
[0104] In one embodiment of the method, the aerosol particles contain a predetermined dose of an active ingredient of the orally inhaled and / or nasal pharmaceutical product. The efficacy parameter can indicate a blood concentration of the active ingredient in the blood. Preferably, a numerical absorption model representing the absorption of the active ingredient contained in the aerosol particles into a bloodstream is used to calculate at least one value of the blood concentration. Alternatively or additionally, the efficacy parameter can indicate a tissue concentration of an active ingredient in the lung tissue. Preferably, a numerical absorption model representing the absorption of the active ingredient contained in the aerosol particles into a lung tissue is used to calculate at least one value of the tissue concentration. A numerical absorption model is preferably based on pharmacometric modeling, which is described in more detail below.Since some drugs are intended to reach the bloodstream (blood plasma) and / or lung tissue via the lungs, especially to achieve a systemic effect in the body, it is of interest to evaluate efficacy based on the concentration of the active substance in the blood and / or lung tissue.
[0105] In one embodiment, the method comprises the following further steps: - determining a predetermined minimum effectiveness value of the effectiveness parameter; - Using the determined at least one aerosol value as a starting value; - adjusting the aerosol value, preferably in an iterative loop in which at least some of the steps of the method according to any one of the preceding claims are repeatedly performed until the calculated effectiveness value is equal to or greater than the predetermined minimum effectiveness value; and - storing the adjusted aerosol value in a storage device, outputting the adjusted aerosol value to a display device and / or providing the adjusted aerosol value for use in evaluating efficacy for pulmonary drug transport as an optimized aerosol value of the aerosol parameter.
[0106] The method can be performed iteratively, preferably controlled by an optimization algorithm. Obtaining an optimized aerosol value is a particular advantage of the described method, since improved (optimized) efficacy values can be utilized in the technical applications described in this disclosure.
[0107] In one embodiment of the method, the at least one aerosol value, in particular if the at least one effectiveness value is equal to or greater than a predetermined minimum effectiveness value of the effectiveness parameter and preferably lower than a predetermined maximum effectiveness value of the effectiveness parameter, is used for one or more of the following: - generating an aerosol comprising aerosol particles containing an orally inhaled and / or nasal pharmaceutical product, preferably using an inhaler device, wherein the aerosol is characterized by the aerosol value, - adjusting a device operating parameter of an inhaler device such that the inhaler device produces an aerosol characterized by the aerosol value, and - designing and / or manufacturing an inhaler device adapted to generate an aerosol characterized by the aerosol value, and - Producing an orally inhaled and / or nasal pharmaceutical product, preferably in the form of a dry powder, characterized by the aerosol value of the aerosol parameter, which is preferably a particle size, a mean particle size and / or a particle size distribution.
[0108] A predetermined minimum efficacy value can define a lower threshold of (desired) efficacy of pulmonary drug transport, in particular above which a (positive and / or desired) medicinal effect of the active ingredient is known or observed (or below which no medicinal effect is known or observed). A predetermined maximum efficacy value can define an upper threshold of (desired) efficacy of pulmonary drug transport, in particular above which a (negative and / or undesirable) effect of the active ingredient is known or observed, in particular (severe or undesirable) side effects or a toxic effect.Accordingly, the application of the method for the described technical applications enables the provision of an aerosol, an inhaler device and / or a pharmaceutical product with a desired efficacy for pulmonary drug transport, in particular causing or enabling a desired medical effect.
[0109] In one embodiment of the method, the at least one effectiveness value, in particular if the at least one effectiveness value is greater than a predetermined minimum effectiveness value of the effectiveness parameter and preferably less than a predetermined maximum effectiveness value of the effectiveness parameter, is used for one or more of the following points: - Evaluating the performance of an inhaler device for pulmonary drug transport, in particular the effect of a setting of a device operating parameter and / or the effect of a device design parameter on the performance for pulmonary drug transport, wherein the inhaler device is configured, in particular when operated with a predetermined setting of a device operating parameter, to generate an aerosol for pulmonary drug transport, such that the aerosol is characterized by the aerosol value of the aerosol parameter, - Evaluation of the efficacy and / or safety of an orally inhaled and / or nasal pharmaceutical product, in particular a dose of an active ingredient of an orally inhaled and / or nasal pharmaceutical product, for pulmonary drug transport, wherein the orally inhaled and / or nasal pharmaceutical product is prepared for administration in the form of an aerosol, preferably using an inhaler device, characterized by the aerosol value of the aerosol parameter, and - Evaluating the efficacy of a drug / device combination product comprising an orally inhaled and / or nasal drug product and an inhaler device for pulmonary drug delivery, wherein the orally inhaled and / or nasal drug product is prepared for administration in the form of an aerosol characterized by the aerosol value using the inhaler device, in particular when operated with a predetermined setting of a device operating parameter, and the inhaler device is configured to generate an aerosol characterized by the aerosol value of the aerosol parameter, in particular when operated with a predetermined setting of a device operating parameter.
[0110] Similarly, as previously described, the application of the described method for the described technical applications enables the design and / or operation of an inhaler device, the manufacture of a pharmaceutical product, or the provision of a drug / device combination product with a desired efficacy for pulmonary drug transport, in particular causing or enabling a desired medicinal effect. In particular, the method can be used to select a suitable combination of an orally inhaled and / or nasal drug and an inhaler device as a suitable (efficient and / or safe) pair for a drug / device combination product.
[0111] Another possible application is that the described procedures for assessing efficacy and / or safety could be used to accelerate and simplify medical or pharmaceutical approval procedures for medical devices or medicinal products by health administrations.
[0112] The invention also relates to a method for evaluating the performance of a pulmonary drug delivery inhaler device, wherein the inhaler device is configured to generate an aerosol comprising aerosol particles containing an orally inhaled and / or nasal drug product, wherein the performance of the pulmonary drug delivery inhaler device is evaluated as a function of the efficacy of the pulmonary drug delivery aerosol when evaluated according to one of the previously described embodiments of the method. The performance of an inhaler is preferably determined based on the efficacy of the pulmonary drug delivery aerosol it generates as a function of device design parameters and / or operating parameters. The effects and advantages of the method are comparable to those of at least one previously described method.
[0113] The invention also relates to a method for evaluating the efficacy and / or safety of an orally inhaled and / or nasal pharmaceutical product for pulmonary drug delivery, wherein the orally inhaled and / or nasal pharmaceutical product is prepared for administration in the form of an aerosol, preferably using an inhaler device, wherein the efficacy of the orally inhaled and / or nasal pharmaceutical product for pulmonary drug delivery is evaluated depending on the efficacy of the aerosol for pulmonary drug delivery when evaluated according to one of the previously described embodiments of the method. The efficacy and / or safety of a pharmaceutical product can be evaluated in comparison to predetermined minimum and / or maximum efficacy values. The effects and advantages of the method are comparable to those of at least one previously described method.
[0114] The invention also relates to a method for evaluating the efficacy of a drug / device combination product comprising an orally inhaled and / or nasal drug product and an inhaler device for pulmonary drug delivery, wherein the inhaler device is configured to generate an aerosol comprising aerosol particles containing the orally inhaled and / or nasal drug product, and the orally inhaled and / or nasal drug product is adapted to be administered in the form of the aerosol using the inhaler device, wherein the efficacy of a drug / device combination product for pulmonary drug delivery is evaluated as a function of the efficacy of the aerosol for pulmonary drug delivery when evaluated according to one of the previously described embodiments of the method.The performance of an inhaler is preferably determined based on the efficacy of the aerosol it generates for pulmonary drug delivery, depending on the device design and / or operating parameters. The efficacy and / or safety of the drug product can be evaluated against predetermined minimum and / or maximum efficacy values. The effects and benefits of the method are similar to at least one previously described method.
[0115] At least one problem underlying the invention is solved by a computer program product comprising instructions that, when executed by a computer, cause the computer to perform at least some (preferably all) steps of the methods described above. The computer program can be executed on a distributed computer system comprising a plurality of computers and / or servers connected via a wireless and / or wired network.
[0116] At least one object underlying the invention is achieved by a computer-readable medium comprising instructions, wherein the instructions, when executed by a computer, implement at least some (preferably all) steps of the previously described methods for evaluating the effectiveness of an aerosol for pulmonary drug delivery.
[0117] The invention also relates to a method for generating an aerosol comprising aerosol particles containing an orally inhaled and / or nasal pharmaceutical product using an inhaler device, the method comprising the following steps: - carrying out the method according to one of the preceding claims; - Providing an orally inhaled and / or nasal pharmaceutical product, in particular based on an efficacy assessment according to a previously described method, in particular when the at least one efficacy value is equal to or greater than a predetermined minimum efficacy value of the efficacy parameter; - Providing an inhaler device, in particular based on an efficacy assessment according to a previously described method, in particular if the at least one efficacy value is equal to or greater than a predetermined minimum efficacy value of the efficacy parameter; - Delivery of the orally inhaled and / or nasal medicinal product to the inhaler device; - Operating the inhaler device, preferably by adjusting a device operating parameter of the inhaler device according to an efficacy evaluation according to a previously described method, in particular when the at least one efficacy value is equal to or greater than a predetermined minimum efficacy value of the efficacy parameter, so that the inhaler device generates an aerosol characterized by the aerosol value of the aerosol parameter.
[0118] The effects and advantages of the method for generating an aerosol are similar to those of the previously described method. Furthermore, the generated aerosol can be used for testing (in a testing process, preferably as part of a design process) an inhaler device, in particular by analyzing properties of the aerosol (aerosol particles) generated by the inhaler device, preferably by measuring at least one aerosol value of the aerosol parameter, and preferably by comparing the determined aerosol value (used as an input value for the simulation) with the measured aerosol value of the aerosol parameter. The inhaler device being tested is preferably a (dry powder) inhaler device, a metered-dose inhaler device, a nebulizer inhaler device, or an inhaler device with a breathing circuit.
[0119] The invention also relates to a method for designing and / or manufacturing an inhaler device adapted to generate an aerosol comprising aerosol particles containing an orally inhaled and / or nasal pharmaceutical product, the method comprising the following steps: - selecting at least one value of a device design parameter characterising an inhaler device; - performing the method described above, wherein preferably the step of determining at least one aerosol value uses a numerical inhaler device model representing the flow of an aerosol in an inhaler device; - Designing and / or manufacturing an inhaler device, in particular based on an efficacy evaluation according to one of the preceding claims, in particular if the at least one efficacy value is equal to or greater than a predetermined minimum efficacy value of the efficacy parameter, so that the inhaler device implements the selected value of the device design parameter.
[0120] The numerical inhaler device model may represent at least one component of the inhaler device characterized by at least one device design parameter. A device design parameter in this method may be one or more of the device design parameters previously described with reference to a numerical inhaler device model. The effects and advantages of the method are similar to at least one previously described method.
[0121] The invention also relates to an inhaler device for administering orally inhaled and / or nasal pharmaceutical products, which is designed and / or manufactured by performing the method steps of the previously described method for designing and / or manufacturing an inhaler device and / or a ventilator. The inhaler device has similar effects and advantages to the at least one previously described method.
[0122] In one embodiment, the inhaler device comprises a ventilation circuit for administering orally inhaled and / or nasal drug products to mechanically ventilated patients. The ventilation circuit preferably comprises a first inlet for an aerosol flow and a second inlet for a ventilation gas flow generated by a ventilation device. Preferably, the ventilation circuit further comprises a common outlet for the aerosol flow and the ventilation gas (air) flow. An aerosol flow generated by a nebulizer device can be supplied to (merge with) a ventilation gas flow generated by the ventilation device and transported jointly into or delivered to the patient via a ventilation circuit.Such an inhaler device has the advantage that an aerosol of an orally inhaled and / or nasal drug product can be administered to a patient who is mechanically ventilated and is unable to use an inhaler device that requires active breathing.
[0123] The invention also relates to a process for the preparation of an orally inhaled and / or nasal pharmaceutical product, preferably in the form of a dry powder, comprising - Carrying out the method according to one of the preceding claims, wherein preferably a particle size characterizing the dry powder is selected as the determined aerosol value; - Producing an orally inhaled and / or nasal pharmaceutical product, preferably in the form of a dry powder, in particular based on an efficacy evaluation of an aerosol characterized by the determined aerosol value according to one of the preceding claims, in particular if the at least one efficacy value is equal to or greater than a predetermined minimum efficacy value of the efficacy parameter, so that the orally inhaled and / or nasal pharmaceutical product is prepared for administration by means of an inhaler device in the form of an aerosol characterized by the aerosol value of the aerosol parameter.
[0124] The particle size characterizing the dry powder preferably corresponds to a (mean) grain size of the solid particles of the dry powder. The (mean) particle size of the dry powder is preferably less than 10 µm, preferably between 1 and 5 µm, particularly preferably between 1 and 3 µm or between 3 and 5 µm. In general, particles between 1 and 3 µm preferably have a systemic therapeutic effect in the body, since relatively smaller particles are (also) deposited in the alveolar region of the lungs and are preferably transported further into the bloodstream. Particles between 3 and 5 µm preferably have a local therapeutic effect in the lungs, since relatively larger particles are (predominantly) deposited in the (conducting) airways and are less likely to reach the alveolar region.
[0125] The invention also relates to an orally inhaled and / or nasal pharmaceutical product, in particular a dry powder, obtained by performing the process steps of the previously described process for producing an orally inhaled and / or nasal pharmaceutical product. The effects and benefits of such a pharmaceutical product are similar to those of the at least one previously described process.
[0126] The invention also relates to a drug / device combination product comprising an orally inhaled and / or nasal drug product and an inhaler device for administering orally inhaled and / or nasal drug products, wherein the drug / device combination product comprises a previously described orally inhaled and / or nasal drug product according to the invention and / or a previously described inhaler device according to the invention. The effects and benefits of such a drug / device combination product are similar to at least one previously described method. Brief description of the drawings
[0127] The invention will be described in connection with further embodiments shown in the figures, wherein Fig. 1 illustrates a method for assessing pulmonary drug transport, Fig.2 shows a schematic representation of the human respiratory system, Fig. Figure 3 shows a schematic representation of a numerical particle transport and deposition model used in the method according to Fig. is used, Fig. Figure 4 shows a detailed view of a schematic representation of a numerical particle transport and deposition model and a numerical absorption model used in the method according to Fig. be used, Fig. Figure 5 shows a schematic representation of a calculated particle transport model implementing a Lagrangian approach as used in the method according to Fig. 1 is used, Fig. Figure 6 shows an illustration of particle transport through an exemplary schematic airway branching during inhalation and exhalation as used in the method according to Fig. 1 is used, Fig.Figure 7 shows a schematic representation of an exemplary library of airway branches used for particle transport in Fig. 6 is used, Fig. Figure 8 shows a schematic representation of a calculated particle deposition model used in the method according to Fig. 1 is used, Fig. Figure 9 shows a schematic representation of a pharmacometric model for determining the efficacy of drugs used in the method according to Fig. 1 is used, Fig. Figure 10a shows a schematic representation of a pressurized metered dose inhaler device and a corresponding numerical inhaler device model, Fig. Figure 10b shows a schematic representation of a breath-activated metered dose inhaler device and a corresponding numerical inhaler device model, Fig.Figure 10c shows a schematic representation of a dry powder inhaler device and a corresponding numerical inhaler device model, Fig. 10d shows a schematic representation of a vibrating mesh nebulizer inhaler device and a corresponding numerical inhaler device model, Fig. Figure 10e shows a schematic representation of a jet nebulizer inhaler device and a corresponding numerical inhaler device model, Fig. 10f shows a schematic representation of an ultrasonic nebulizer inhaler device and a corresponding numerical inhaler device model, Fig. 10g shows a schematic representation of a nebulizer inhaler device comprising a breathing circuit system and a corresponding numerical inhaler device model, and Fig.Figure 11 shows a representation of different methods for assessing pulmonary drug transport. Detailed description
[0128] In the following description, the same reference numerals are used for elements that have the same or a similar effect. In general, reference numerals that include a quotation mark ('), e.g., 4', 40', or 30', refer to discretized (modeled / numeric) quantities, while corresponding reference numerals without a quotation mark, e.g., 4, 40, or 30, refer to the corresponding (real) physical quantities.
[0129] The Fig. The method shown in Figure 1 is suitable for measuring the effectiveness of an aerosol 3 (see e.g. Fig.2) for pulmonary drug transport, wherein the aerosol 3 comprises aerosol particles 30 containing an orally inhaled and / or nasal drug product 1. The (real) aerosol particles 30 are represented by discrete (modeled) aerosol particles 30'.
[0130] A (single) patient-specific tomographic image Img of the respiratory system 4 of an individual human being is obtained by applying an imaging technique, e.g., by taking a (single) CT scan of the specific respiratory system 4. Other imaging techniques such as computed tomography (CT), in particular magnetic resonance imaging (MRI), ultrasound, X-rays, or electrical impedance tomography (EIT) can also be used. The (human) individual can be healthy or a patient with a lung disease. The tomographic image Img is processed in a segmentation step known from the prior art, resulting in processed image data representing the respiratory system 4. Subsequently, a discretized respiratory system structure 4' is derived from the processed image data. A numerical lung model Lmod (lung model) based on the discretized respiratory system structure 4' is created and calibrated.Based on a respiration value Rval of a respiration parameter Rpar, which characterizes the respiration of the human individual, suitable boundary conditions for the lung model Lmod are derived. The lung model Lmod is described below with reference to . Fig. 2 described in more detail.
[0131] The discretized respiratory system structure 4' is based on a spatial segmentation of the structure of the airways 40 of the respiratory system 4 into a plurality of discrete, spatially three-dimensional (tubular) airway segments 40'. The discrete airway segments 40' can be so-called finite elements of an FEM discretization (FEM: Finite Element Method). In a next step, the transient gas flow Gvel in the airways 40, which is modeled by the plurality of discrete airway segments 40', is calculated in a reduced, three-dimensional flow simulation, preferably as a 0D flow.
[0132] Subsequently, based on the transient gas flow velocity Gvel, a numerical particle transport and deposition model Pmod (Particle Transport and Deposition Model) is used in a one-way coupled approach to calculate a spatial particle deposition distribution Ddist of a multitude of individual discrete particles 30' deposited in the airways 40, particularly in the lungs 42. The inhalation and exhalation of the individual particles 30' are accounted for by the particle transport and deposition model Pmod. Individual discrete particles 30' are inserted into the computation domain and individually tracked across the entire airway tree of the discretized respiratory system structure 4' according to a Lagrangian approach.
[0133] The plurality of discrete particles 30' individually tracked through the airway segments 40' represent aerosol particles 30 of an aerosol 3 containing an orally inhaled and / or nasal pharmaceutical product 1, in particular an active ingredient of an administered pharmaceutical product, preferably for the treatment of a lung disease. Orally inhaled and / or nasal pharmaceutical products 1 are preferably intended for the treatment of lung diseases, but are not limited thereto, and may in particular comprise cannabis (THC as the active ingredient).
[0134] At least one aerosol value Aval of at least one aerosol parameter Apar characterizing the aerosol 3 is determined, preferably measured, from a database or from specification data of an inhaler device 2, 2a-d for generating an aerosol 3. An aerosol value Aval can also be calculated based on analytical relationships of physical properties of the aerosol 3 or as a result of a numerical simulation of a generation process and / or a flow of the aerosol 3 in an inhaler device 2, 2a-d. For such a simulation, a numerical inhaler device model Dmod can be used (see Fig. 3 and in particular Fig.10a-g). Typical aerosol parameters can be the (mean) particle size, preferably a (mean) particle size distribution, particle density, and / or an aerosol flow (mass flow or volume flow), which is preferably time-dependent relative to a respiratory cycle of a human individual (patient-specific).
[0135] In a post-processing step, at least one effectiveness value Eval of an effectiveness parameter Epar is calculated based on the spatial particle deposition distribution Ddist. In the example of Fig.1, the efficacy parameter Epar represents a set of different parameters, including the percentage of particles deposited in a target area of the lung (Eval = 12%), a mean particle size in the target area [µm] (Eval = 2.2 µm), the standard deviation of the particle size in the target area [µm] (Eval = 1.5 µm), and the amount of drug absorbed in the target area [mg] (Eval = 0.01 mg). Different types of efficacy values Eval and further specific examples are discussed below with reference to the examples.
[0136] The efficacy value Eval can be used to automatically evaluate the efficacy of pulmonary drug transport. The efficacy value Eval can be stored, displayed, and / or transmitted for further use in various technical applications. In particular, the efficacy value Eval can be used to evaluate the efficacy and / or safety of an orally inhaled and / or nasal drug product 1 or to evaluate the performance of an inhaler device 2, 2a-d for pulmonary drug transport, e.g., during a design or testing process of the inhaler device 2, 2a-d.
[0137] Orally inhaled pharmaceutical products 1 may include the examples of active ingredients described below. Currently, many different formulations of orally inhaled pharmaceutical products are approved by regulatory authorities for oral inhalation. Many existing consumer pharmaceutical products are based on different active ingredients for different diseases. These active ingredients can be divided into the following main groups according to their main pharmacological groups: Inhaled bronchodilators are used to treat obstructive airway diseases such as asthma and COPD.Subgroups of these inhaled bronchodilators include β2-adrenoceptor agonists (example active ingredients are epinephrine, albuterol, terbutaline, levalbuterol, fenoterol, aformoterol, formoterol, indacaterol, olodaterol, and salmeterol) and muscarinic acetylcholine receptor antagonists (example active ingredients are ipratropium, tiotropium, glycopyrronium, aclidinium, umeclidinium, and revefenacin). Anti-inflammatory agents include glucocorticoids for the treatment of inflammation of the lung tissue, e.g., in asthma. The active ingredients include beclomethasone dipropionate, budesonide, ciclesonide, flunisolide, fluticasone furoate, fluticasone propionate, and mometasone furoate. Combination preparations are also included, which combine the aforementioned active ingredients for the treatment of COPD and asthma; anti-infectives are used for infectious diseases such as tuberculosis, influenza, pneumonia, measles, and severe acute respiratory syndrome.Active ingredients are tobramycin, aztreonam lysinate, levofloxacin, colismethate sodium, amikacin, ribavirin, and pentamidine. Recombinant human deoxyribonuclease (rhDNase) is a glycosylated 260-amino acid protein used to treat cystic fibrosis. Mannitol is a non-ionic sugar alcohol in dry powder form used to increase the periciliary fluid layer. This medication induces coughing and thus clears the airways in bronchiectasis and cystic fibrosis. Prostacyclins are used to treat pulmonary arterial hypertension (PAH) and contain iloprost and treprostinil as active ingredients. Lung surfactant is administered by oral inhalation to treat respiratory distress syndrome (RDS), particularly in infants.Lung surfactant is either extracted from animal lungs or produced synthetically; drugs for systemic therapy are used to treat systemic diseases that are not limited to purely respiratory diseases. Active ingredients include nicotine, loxapine, levodopa (for the treatment of Parkinson's disease), or insulin (for the treatment of diabetes).
[0138] Fig. illustrates the structure of the human lung and serves to explain the calculated numerical lung model Lmod in more detail below.
[0139] In medical literature, 23 airway generations of the human lung are usually distinguished (see Fig.), which include the trachea 46 (generation 0), the bronchi 47, consisting of the main bronchi (generation 1), the lobar bronchi (generation 2), the segmental bronchi (generations 3 and 4) and the subsegmental bronchi (generations 5-11), the bronchioles 48 (generations 12-19), containing the terminal bronchioles (generation 16) and the respiratory bronchioles (generations 17-19), and the alveoli 49, containing the alveolar ducts (generations 20-22) and the alveolar sacs (generation 23). Generations 1-16 are generally assigned to the conducting airways and generations 17-23 to the respiratory airways. Within the conducting airways, each generation corresponds to a stage of airway branching. The lungs 42 are located within the thorax 8 and above the diaphragm 43.
[0140] More precisely, the (human) respiratory tract 40 is divided into the trachea 46 and the bronchial system, which is divided into a right and a left main bronchial branch (main bronchus) and supplies one of the two lungs with oxygen. Each bronchial trunk is further divided into smaller bronchi (second-order bronchi): The right main bronchus usually branches into three main branches, which usually supply the three lobes of the right lung. The left main bronchus usually divides into two main branches, which usually supply the two lobes of the left lung. These five main branches form the so-called lobar bronchi, which further branch out into the segmental bronchi and into increasingly smaller branches (generations). After about 22 branching levels (i.e. 23 generations), a widely branched system of the bronchial tree is created.
[0141] This system of bronchi 47 is available via the CT image dataset and can be converted or segmented into a 3D structural dataset using, for example, an artificial intelligence-based image recognition algorithm. This dataset is then made available to the lung model for constructing the lung model geometry.
[0142] The smaller the bronchi become, the simpler and thinner their internal structure becomes. The smallest branches of the bronchi, the bronchioles (48), have an internal diameter of less than 1 mm. Therefore, CT resolution is insufficient to visualize these structures with spatial resolution. While the lower-generation airways are segmented directly from the CT data, the higher-generation airways are generated using a space-filling algorithm, as described, for example, in "Ismail M, Comerford A, Wall W A. Coupled and reduced dimensional modeling of respiratory mechanics during spontaneous breathing. International Journal of Numerical Methods in Biomedical Engineering 2013; 29:1285-1305." The airways (trachea and bronchial tree) are generated recursively starting from the generation in which segmentation from the CT data is no longer possible, or earlier, until the peripheral airways meet a length cut-off criterion (e.g. 1.2 mm), a radius cut-off criterion (e.g.0.2 mm) or a generation termination criterion (e.g., Ngen=17) is met. The scaling of the radius of the daughter-parent branch of the left and right branches of the bronchial tree is 0.876 and 0.686, respectively, as commonly known from morphological studies of the human body. The radius scaling, the orientation of the airways, and the airway length can be adjusted depending on the spatially associated CT data to depict the inhomogeneity of the lung. The segmented airways of the lower generation, based on the CT data, are connected to the airways of the higher generation generated using the space-filling algorithm. At the distal end of the generated airway tree, so-called terminal units are created that model the rest of the airway system, which may include alveoli (49), alveolar ducts, alveolar sacs, and / or parts of the bronchioles (48). Together, the terminal units form what is referred to here as lung tissue 6.
[0143] In the following, a lung model is understood to be a digital, i.e., computer-implemented model of a human lung that is suitable for simulating the physiology of a human lung. This can be a lung model Lmod that is based on a patient's CT data, i.e., is patient-specific. Alternatively, the lung model Lmod can also be based on the evaluation of CT data from a patient group or, more generally, on the evaluation of lung data from a database. A patient-specific lung model Lmod can be calibrated to a patient, e.g., by calibrating the lung model using a real respiratory (volume) curve of the patient.
[0144] The output variables of the simulation based on the lung model Lmod include in particular the pressure P and the flows Q in each airway segment 40', but may also include the stretch of the lung tissue and / or a surface-active factor of the alveolar surface.
[0145] The lung model Lmod considers (i) the airways 40, consisting of the trachea 46, the bronchi 47, and the bronchioles 48, (ii) the terminal units, and preferably (iii) the terminal unit interaction, which considers the viscoelastic coupling of adjacent terminal units. During inspiration, the lung volume increases, causing, among other things, an expansion of the alveoli 49. In this case, the adjacent alveoli 49 are interconnected in their expansion by the lung tissue 6 that connects them.
[0146] Terminal cluster linker elements are used to model the interaction between neighboring terminal units and between terminal units and airways. These terminal cluster linker elements connect, in pairs or groups, those terminal units (and airways) that influence each other. This interaction is caused by the volume competition between neighboring alveoli / alveolar sacs within the lung tissue. The resulting mutual influence is realized by additional forces on the terminal units (and airways) connected to the terminal unit linker element. This allows the terminal units to be stretched even if the pressure is only exerted on the subpleural terminal units. In other words, the pleural pressure boundary condition is only applied to the terminal units that actually border the pleural space.
[0147] The lung model Lmod considers the three-dimensional geometric structure of a patient's lung. A dataset representing the 3D structural geometry of a patient's lung (discretized respiratory system structure 4') is read into the lung model Lmod as an input variable.
[0148] In one embodiment, the dataset can alternatively be adjusted using the structural geometry of a plurality of patients. For example, an averaged structural dataset (averaged discretized respiratory system structure 4') can be created for patients with a specific pre-existing lung disease and read into the lung model Lmod to evaluate the efficacy of pulmonary drug transport for that specific lung.
[0149] The lung model Lmod follows an approach in which the pressure difference ΔP along an airway segment 40' is represented as a linearly dependent variable of the flow resistance R and the flow velocity Q through the airway channel as ΔP=Q*R.
[0150] Further details and a mathematical description of the lung model Lmod are contained in WO 2021 / 204931 A1 and the references cited therein.
[0151] The lung model Lmod represents the entire human lung and takes into account the elasticity of the airway walls 50 and the lung (alveolar) tissue 6. Consequently, the lung model Lmod also takes exhalation into account, as the elastic reaction forces that compress the lung during exhalation are taken into account.
[0152] Fig. shows the spatial particle deposition distribution Ddist calculated based on the numerical particle transport and deposition model Pmod in detail.
[0153] The numerical inhaler device model Dmod represents the aerosol flow in a mouthpiece 20 (discretized mouthpiece 20') of an inhaler device 2, 2a-c and the numerical mouth model Mmod takes into account the aerosol flow in the area of the mouth 41, the pharynx 44 and the larynx 45. Dmod and Mmod can be based on a CFD model that takes particle transport into account, preferably a 3D CFPD model.
[0154] The method comprises a step of inserting individual discrete particles 30' into the gas flow in the airways 40. The insertion of particles can be understood as the initialization of (new) particles that are to enter the numerical domain. It is important that particle transport is represented and solved in 3D space, as explained in more detail below. At discrete times, individual discrete particles 30' are inserted into (at least one location of) the lung model domain, preferably into an inflow cross-section of the trachea 46, by initializing at least one Lagrangian particle 30' with its corresponding position, velocity, acceleration, density, mass, drag coefficient, radius, or shape information, and corresponding dimensions.The number of particles deployed and their individual properties and onset times can be determined in various ways to correspond to the real aerosol properties at the deployment position, e.g. from (any combination of): a directly specified list of values; measured values obtained from an experiment; values determined as a result of another computer model and simulation, e.g., comprising the aerosol generation process and / or flow and / or the upper respiratory tract; values determined as a solution to an analytical model, e.g., comprising the aerosol generation process and / or flow and / or the upper respiratory tract; and randomly generated values corresponding to a statistical distribution obtained by any of the previous options.
[0155] For illustration, two specific application cases will be described in more detail. Starting from a time-dependent aerosol mass rate, a time-dependent particle size distribution (e.g., log-normal distribution with mass median diameter and geometric standard deviation, as measured for the inhaler in an experiment), a constant particle density, and a spherical shape of the particles, an ensemble of discrete particles 30' is generated by randomly assigning a diameter drawn from the log-normal distribution and calculating / assigning the remaining properties such as density, mass, and drag coefficient. Particle generation for the currently considered discrete time interval is stopped as soon as the target aerosol mass for this time interval is reached. The specific insertion position of each individual particle within the cross-section at the tracheal inlet, i.e.at the inflow, is randomly chosen based on the assumption of a uniform distribution of particles per cross-sectional area.
[0156] Fig.Figure 4 illustrates the particle transport and deposition of aerosol particles 30 at the level of the alveoli 49 using the numerical particle transport and deposition model Pmod. The aerosol particles 30 contain a predetermined dose of an active ingredient of the orally inhaled and / or nasal pharmaceutical product 1, which can be absorbed into the bloodstream 5 in the alveoli 49. A numerical absorption model Amod is evaluated to account for the absorption into the bloodstream 5 of the active ingredient contained in the aerosol particles 30, which has deposited in the alveoli 49, i.e., in the terminal units comprising the alveoli 49. The numerical absorption model Amod is preferably based on pharmacometric modeling, in particular on first-order kinetics, Michaelis-Menten kinetics, or parallel first-order kinetics plus Michaelis-Menten kinetics.Pharmacometric modeling allows for the assessment of drug concentrations at any time point, e.g., in plasma, as well as drug efficacy. The efficacy parameter Epar can indicate a blood concentration (e.g., [mg / ml]) of the drug in the blood.
[0157] Fig.illustrates how 3D particle transport through the airways is represented by a 0D fluid field, which saves computational resources despite the high spatial resolution of the airway tree and makes the method computationally affordable. This important advantage of the method is achieved by using 3D particle dynamics in a Lagrangian formulation to model aerosol transport through the airways 40. The information from the fluid field required to calculate the coupling forces on the discrete particles 30' (e.g., drag force Df, buoyancy force Bf, gravitational force Gf, and optionally Brownian motion force BMf) is obtained by reconstructing the 3D fluid field from the solution of the reduced-dimensional fluid field. The numerical particle transport and deposition model Pmod implements a Lagrangian approach to track individual discrete particles 30' transported by the gas flow Gvel.The Lagrangian formulation is a one-way coupled approach, which means that the effects of transient gas flow in the airways on the particles are taken into account, but not vice versa.
[0158] The reconstructed velocity profile Velprof is based on the assumption of a radially symmetric, parabolic flow profile in a cylindrical airway segment 40' (see Fig. ). Given the radius of the airway segment and the volumetric flow and pressure at the inlet and outlet from the 0D fluid solution, the flow velocity and pressure (as well as their gradients and other derived quantities) can be calculated at any point in the 3D domain.
[0159] Alternatively, other assumptions can be made for the dimensionality reduction from 3D to 0D and vice versa, e.g., conical airways or a different flow profile. However, the concept of dimensionalizing the fluid field, solving the reduced dimension problem, and reconstructing the full-dimensional fluid field to calculate the forces exerted on the transported particles remains the same.
[0160] Fig.illustrates the approach of particle transfer between the individual airway segments 40', 40a', 40b', 40c'. This special approach for the transfer of discrete particles 30' across airway branches is necessary because the 0D fluid field is discontinuous at the boundaries of the individual airway segments 40', 40a', 40b', 40c'. When simulating a discrete particle 30' in a 0D fluid consisting of individual airway segments 40', a transfer is initiated when the particle leaves the upstream airway segment 40a'. The discrete particle can be simulated either with a purely geometric approach (geometric branching criterion) or with additional information resulting from an interpolation approach using a branching library Lib bifurcare transferred to one of the downstream airway segments 40b' and 40c'. Similarly, during exhalation, the particles are transported in the opposite direction when they exit one of the downstream airway segments 40b' and 40c'.
[0161] Fig. illustrates the process of creating a library for airway branches Lib bifurc , which stores a variety of different pre-calculated airway branching scenarios. The airway branching library Lib bifurc can be used for the transfer of discrete particles 30' across airway branches. This airway branch library Lib bifurcContains pre-calculated particle transfer information from numerous pre-calculated 3D CFPD simulations. These 3D CFPD simulations exhibit various flow regimes, branching geometries, and aerosol parameters Apar. This results in various pre-calculated airway branching scenarios (Bifurc1, Bifurc2, Bifurc3, ... Bifurcr). Pre-calculated branching scenarios can be based on relatively complex pre-calculated three-dimensional simulations of branches with high spatial and temporal resolution, preferably also considering turbulent flow for different branching geometries. A pre-calculated branching scenario is preferably used for the more complex branching scenarios in the inspiratory flow direction, while a purely geometric branching criterion can be used in the (reverse) exhalation flow direction.
[0162] Fig.is an example of the two particle deposition mechanisms that typically occur in the lungs.
[0163] According to the first deposition mechanism, a deposition model based on various deposition criteria is evaluated for each discrete particle 30. The deposition model is preferably a submodel (subroutine) of the numerical particle transport and deposition model Pmod. These deposition criteria indicate a comparison of the distance value Wval between a discrete particle 30' and the airway wall 50' of the airway segment 40' with a predefined deposition distance Dval. Deposition occurs if the distance value Wval is smaller than the deposition distance Dval. Further deposition criteria can be the current particle velocity Pvel, the angle of impact between the discrete particle 30' and the airway segment 40', the shape of the discrete particle 30', or attractive forces between the discrete particle 30' and the airway segment 40'.
[0164] The second deposition mechanism occurs when a discrete particle 30' reaches the end of a terminal airway segment 40'. The particle 30' is deposited in the associated terminal unit, which represents individual alveoli 49 or a larger area within the lung.
[0165] The spatial particle deposition distribution Ddist is calculated based on all deposited particles within the discretized respiratory system structure 4', which includes the airway segments 40' representing the airways 40 and the terminal units representing the alveoli 49.
[0166] Fig.shows the pharmacometric modeling for calculating the blood (plasma) concentration of the drug as an example for determining the drug's efficacy. The results of the particle transport and deposition simulation with Pmod, in particular a spatial particle deposition distribution Ddist, can be used as inputs for a subsequent pharmacometric model to evaluate drug exposure, i.e., the drug concentration at any time point, e.g., in plasma, as well as the drug effect. In particular, pharmacokinetic (PK) models can be used to relate the locally deposited dose to the time course of the measured drug concentration in the body (usually in plasma).
[0167] For the described method, a PK model with a compartmental structure with input and disposition models is used. The input model describes the temporal course of drug movement from a region or sub-area of deposition to the side of drug measurement, e.g., in the plasma. The disposition model, on the other hand, describes the temporal course of distribution, metabolism, and excretion of the drug from the body. A preferred variant is in Fig. shown schematically.
[0168] Based on a calculated spatial deposition distribution Ddist in the lung, the doses Dsub1, Dsub2, ..., Dsubn of the drug can be calculated for arbitrary subdomains Lungsubd1, Lungsubd2, ... Lungsubdn of the lung model. These subdomains can be based on a spatial subdivision of the discretized structure of the respiratory system 4', e.g., a peripheral and a central region, or based on the generation of airways, e.g., conducting airways and respiratory airways. For each lung subdomain Lungsubd1, Lungsubd2, ... Lungsubdn or each compartment, absorption can be modeled by first-order kinetics, Michaelis-Menten kinetics, or parallel first-order kinetics plus Michaelis-Menten kinetics. Similarly, the systemic disposition can be modeled by one or more compartments, a central compartment Centcomp and peripheral compartments Pcomp1, Pcomp2, as in Fig.Mucociliary clearance Muccl can be modeled by one or more separate first-order elimination processes.
[0169] The parameters of the PK model, consisting of at least one or more absorption half-lives (tMuccl, tsub1, tsub2) and one or more clearances CLdcomp1, CLdcomp2, CL, can be calculated using state-of-the-art methods for population PK models, as described in (Bauer RJ, Guzy S, Ng C. A survey of population analysis methods and software for complex pharmacokinetic and pharmacodynamic models with examples. AAPS J. 2007; 9(1):E60-E83. doi:10.1208 / aapsj0901007) in combination with data, preferably from time-course measurements of the plasma concentration of the drug.
[0170] Fig.10a-10g show various inhaler devices 2, 2a-d capable of generating aerosols 3 containing orally inhaled and / or nasal medicament products 1 containing an active ingredient of the medicament. The aerosol 3 contains a carrier gas 31 and aerosol particles 30 that can be inhaled by a person. Fig. 10a and Fig. 10b show metered dose inhalers 2a, Fig. 10c shows a dry powder inhaler 2a, Fig. 10d-f show nebulizer inhaler devices and Fig. 10g shows a nebulizer inhaler device 2d having a ventilation tube system 24 for mechanical ventilation.
[0171] The generation process and flow of aerosol 3 in the respective inhaler devices 2, 2a-d (inhaler) are represented by corresponding numerical inhaler device models Dmod. An aerosol value Aval of an aerosol parameter Apar, which characterizes the aerosol 3 generated in the respective inhaler devices 2, 2a-d, can be determined by simulating the generation and flow of aerosol 3 using the numerical inhaler device models Dmod. For example, the aerosol flow in the inhaler device 2, 2a-d can be calculated using a 3D CFD simulation on the discretized domain of the geometry of the inhaler device 2 and its components, obtained, for example, from a CAD model. The calculated aerosol value Aval is then used as input for the numerical particle transport and deposition model Pmod to determine the effectiveness of aerosol 3 for pulmonary drug transport.
[0172] The numerical inhaler device models Dmod may depend on one or more device design parameters Ddpar and / or device operating parameters Dopar, which may vary depending on the type of inhaler device 2, 2a-d. A respiratory value Rval, which indicates a respiratory parameter Rpar, such as an inhalation gas flow and / or an inhalation suction pressure, may be specified as a boundary condition for the numerical inhaler device model Dmod at the outlet of the inhaler device 2, e.g., at an outflow opening of a mouthpiece 20, i.e., at a discretized mouthpiece 20' of the Dmod model.
[0173] Fig.Figure 10a shows a metered-dose inhaler device 2b (inhaler), namely a pressurized metered-dose inhaler (pMDI). The inhaler 2b comprises a canister 21 and an actuator 27. The canister 21 contains a substance comprising an orally inhaled pharmaceutical product 1 (liquid) and a propellant 26, so that the substance is pressurized. The canister 21 also contains a valve 29. The actuator 27 comprises an actuator seat 28, a nozzle 22, and a mouthpiece 20. When the canister 21 (cartridge) is inserted into the actuator 27, the valve 29 is inserted into the actuator seat 28. As the canister 21 is pushed further toward the actuator 27, the valve 29 is pressed against the actuator seat 28, activating the valve 29 and releasing all or part of the pharmaceutical product 1 (medication) through the nozzle 22 in the form of aerosol particles 30. The aerosol particles 30 exit the actuator 27 through the mouthpiece 20.
[0174] Fig.Figure 10b shows a metered-dose inhaler device 2b (inhaler), namely a breath-activated metered-dose inhaler (BAMDI). The inhaler 2b comprises a canister 21 and an actuator 27. The canister 21 contains a substance comprising an orally inhaled pharmaceutical product 1 (liquid) and a propellant 26 such that the substance is pressurized. The canister 21 contains a valve 29. The trigger 27 comprises a lever 60, a first spring 61, a second spring 62, a vane 63, a trigger mechanism 64, an actuating seat 28, a nozzle 22, and a mouthpiece 20. When the lever 60 is preloaded, the first spring 61 is tensioned, and the canister 21 is pressed against the activation mechanism 64. When a negative pressure, in particular a suction pressure Rval, is applied to the mouthpiece 20, the wing 63 is pulled towards the mouthpiece 20, thereby triggering the activation mechanism 64.When the activation mechanism 64 is triggered, the associated valve 29 is pressed against the actuating seat 28, activating the valve 29 and releasing at least a portion of the pharmaceutical product 1 in the form of aerosol particles 30 through the nozzle 22. The aerosol particles 30 exit the actuator 27 through the mouthpiece 20. While the activation mechanism 64 is triggered, the second spring 62 is under tension. When the negative pressure at the mouthpiece 20 ceases, the second spring 62 deactivates the activation mechanism 64, and the release of the aerosol particles 30 is stopped.
[0175] Several device design parameters Ddpar of metered-dose inhaler devices 2b can be varied to improve pulmonary drug transport to specific regions of the lung. For example, the diameter and / or geometry of the nozzle 22 and / or the distance between the nozzle 22 and the mouthpiece 20 influence the particle size distribution. The pressure inside the container 21 is a device operating parameter Dopar that influences the velocity of the ejected drug 1.
[0176] Fig.shows a dry powder inhaler device 2a (DPI) that can be configured as a single-dose DPI, a multiple unit-dose DPI, or a multi-dose DPI. The inhalation device 2a comprises a canister 21 and an actuator 27. The canister 21 contains a pharmaceutical product 1 to be inhaled orally in the form of a dry powder. A propellant 26 may also be contained in a pressurized container 21. The actuator 27 comprises an actuator 71, a spring 61, a metering mechanism 70, and a mouthpiece 20. When the actuating cap 71 is depressed, the metering mechanism 70 is activated, and at least a portion of the pharmaceutical product 1 is released from the container 1 as solid aerosol particles 30 through the mouthpiece 20.
[0177] The effectiveness of the dry powder inhaler device 2a for pulmonary drug delivery can be influenced by adjusting the particle size of the preloaded dry powder. The geometry of the mouthpiece 20 is a device design parameter Ddpar, which can influence the flow of the aerosol 3 and thus also the velocity of the particles 30 during inhalation.
[0178] Fig.10d shows a nebulizing inhaler device 2c (inhaler), namely a vibrating mesh nebulizer (VMN). The inhaler 2c is configured as an actively vibrating mesh nebulizer or a passively vibrating mesh nebulizer. The inhaler 2c comprises a reservoir filled with a liquid, orally inhaled pharmaceutical product 1, here a canister 21, a mesh 80 (or a membrane), and a mouthpiece 20. The mesh 80 can be connected to a power source (not shown). When the mesh 80 vibrates, a portion of the pharmaceutical product 1 is nebulized and released through the mouthpiece 20, so that the particles 30 form droplets. The mouthpiece 20 can be configured as an inhalation mask through which a patient can inhale through the mouth and / or nose.
[0179] Fig.shows another type of nebulized inhaler device 2c (inhaler), namely a jet nebulizer (JN). The inhaler 2c comprises an aerosol generating chamber 23 containing a liquid pharmaceutical product 1 to be inhaled orally, and a mouthpiece 20. A gas source (not shown) for a carrier gas 31 forms a high-pressure gas jet 82 that enters the aerosol generating chamber 23 from below to generate aerosol particles 30 in the form of droplets. The aerosol particles 30 are discharged from the aerosol generating chamber 23 together with the carrier gas 31 as a flow of aerosol 3 through the mouthpiece 20. The inhaler shown may include a deflection plate 81, which serves to deflect larger aerosol particles and thus generate an aerosol 3 with relatively small particles (droplets) 30.
[0180] Fig.Figure 10f shows another type of nebulized inhaler device 2c (inhaler), namely an ultrasonic nebulizer (UN). The inhaler 2c comprises an aerosol generating chamber 23 containing a liquid pharmaceutical product 1 (medication) to be inhaled orally, and a mouthpiece 20. When the vibrating component 83 is vibrated, at least a portion of the pharmaceutical product 1 is nebulized into aerosol particles 30. The vibrating component may comprise or be a piezoelectric crystal. The aerosol particles 30 are released from the generating chamber 23 through the mouthpiece 20. The inhaler 2c may further comprise a deflection plate 81 to deflect larger aerosol particles 30 and prevent them from leaving the generating chamber 23.
[0181] The effectiveness of nebulized inhaler devices 2c, also referred to as soft mist inhalers (SMI), for pulmonary drug delivery could be improved by adjusting, in particular optimizing, certain device operating parameters Dopar, such as the frequency at which vibrating mesh nebulizers (VMN) or ultrasonic nebulizers (UM) operate. Furthermore, device design parameters Ddpar, such as the geometry of the mouthpiece 20 and / or the baffle plate 81, as well as the dimensions of the aerosol generating chamber 23, can be appropriately selected during a design process of an inhaler device 2c to influence the aerosol parameters Apar and thus improve the effectiveness of the inhaler 2c for pulmonary drug delivery.The surface tension and / or viscosity of a particular liquid pharmaceutical product 1 may also influence the aerosol generation process (nebulization) and thus the properties of the generated aerosol 3, in particular the size (diameter) of the particles 30.
[0182] Nebulizer inhaler devices 2c may further comprise an aerosol storage chamber and an inhalation valve and / or an exhalation valve, wherein the aerosol storage chamber can capture and temporarily store a volume of already generated aerosol while the patient exhales. The exhalation valve may be integrated into a mouthpiece 20.
[0183] For inhaler devices with a rotating disc (not shown), the drug delivery efficiency can be influenced by adjusting the rotation speed of the disc as the device operating parameter Dopar and / or by choosing a suitable groove geometry on the rotating disc as the device design parameter Ddpar.
[0184] Fig.Figure 10g shows an inhaler device 2d comprising a ventilation circuit (24) for administering orally inhaled and / or nasal drug products to mechanically ventilated patients. The ventilation circuit comprises a first inlet for an aerosol flow and a second inlet for a ventilation gas flow (air or oxygen) generated by a ventilation device (not shown). The ventilation circuit 24 has a common outlet 24c for the mixed aerosol / ventilation flow. The aerosol 3 is generated by a nebulizer device 25, which may operate according to the aerosol generation principle of one of the previously described nebulizer inhaler devices 2c or other nebulizer types. The ventilation gas flow receives the aerosol from the outlet of the nebulizer device 25.A setting of the ventilation device that determines the ventilation gas flow can be a device operating parameter Dopar, which influences the aerosol flow at the common outlet. The nebulizer device 25 is integrated into the ventilation tube 24, which is inserted into the patient's respiratory system for mechanical ventilation. The aerosol enters the patient's respiratory system at the outlet of a ventilation tube system. With such an inhaler device 2d, orally inhaled and / or nasal pharmaceutical products 1 can be administered to mechanically ventilated patients who are consequently unable to actively breathe (inhale).
[0185] Fig. Figure 11 illustrates various methods comprising steps for evaluating pulmonary drug transport, in particular according to the Fig. 1. Similar to Fig.As explained in Figure 1, an inhaler device 2 generates an aerosol 3 from an orally inhaled pharmaceutical product 1, which may, for example, be a liquid to be nebulized or a dry powder. The aerosol 3 consists of liquid (droplet particles of a liquid substance) or solid (powder particles) aerosol particles 30 and a carrier gas 31. An aerosol parameter Apar physically characterizes the aerosol 3. A tomographic image Img, e.g., a CT scan, of an individual (human) respiratory system 4, which includes the lungs, forms the basis for a calculated numerical lung model Lmod. A respiratory value Rvar of a respiratory parameter Rpar, which characterizes the respiratory behavior (respiratory properties) of the respiratory system 4, is derived from the measurement of a respiratory rate of the individual (patient). The respiratory rate can be a time course of the inhaled and exhaled air volume during a full respiratory cycle of the individual (patient).The measurement is preferably performed using a spirometer. A numerical inhaler device model Dmod is derived depending on the structure of the inhaler device 2. Dmod depends on (is parameterized by) the device design parameters Ddpar and / or the device operating parameters Dopar. The numerical device model Dmod is used to simulate the generation and / or flow of an aerosol 3 containing individual discrete aerosol particles 30'.
[0186] The aerosol value Aval of the aerosol parameter Apar is determined based on the simulation of the inhaler device 2 using the numerical inhaler device model Dmod. Alternatively (see dashed arrow Aval in Fig.11), instead of or in addition to modeling the aerosol flow in the inhaler device 2, one or more aerosol values Aval can be determined in another way, for example by measuring the aerosol parameter Apar of the aerosol 3. To measure particle sizes or particle size distributions of the aerosol 3, for example, optical and / or aerodynamic methods are preferably used, e.g. using a laser aerosol spectrometer or an aerodynamic particle sizer. The aerosol value Aval could also be obtained from a database containing data indicating the physical properties of the aerosol 3 or from specification data of the inhaler device 2 and the type of aerosol 3 generated by it, in particular depending on specific settings of the device operating parameters of the inhaler.
[0187] Based on the gas flow velocity Gvel in the discretized airways 40' calculated using the lung model Lmod, the numerical particle transport and deposition model Pmod calculates the spatial particle deposition distribution Ddist, preferably a local spatial density of the deposited aerosol particles in various regions of the respiratory system 4, in particular the lungs. Based on the spatial particle deposition distribution Ddist, one or more values Eval of an efficacy parameter Epar are calculated. The efficacy parameter Epar preferably indicates a locally effective dose of the pharmaceutical product 1, for example, a blood concentration of the active ingredient of the pharmaceutical product 1 in the bloodstream 5 or a tissue concentration in the lung tissue 6. Such a blood concentration Eval can be calculated based on Ddist using an additional absorption model Amod.A predetermined minimum efficacy value Eval_min can define a lower threshold for a desired efficacy of pulmonary drug transport, above which a desired medicinal effect of the active ingredient is observed. A predetermined maximum efficacy value Eval_max can define an upper threshold for a desired efficacy of pulmonary drug transport, above which an undesirable effect of the active ingredient is observed, in particular undesirable side effects or even a toxic effect. Preferably, Eval lies between Eval_min and Eval_max for an aerosol value Aval that is well suited for pulmonary drug transport.
[0188] The efficacy of the orally inhaled pharmaceutical product 1 for pulmonary drug transport, in particular of the active ingredient contained in the orally inhaled pharmaceutical product 1, is automatically evaluated, e.g., by means of a computer, based on the efficacy value Eval. In particular, Eval could be stored in a storage device (not shown), displayed by means of a display device (not shown), and / or transmitted via a transmission device (not shown), e.g., via mobile communication, for use or further processing at another location, in particular in a local or remote computer network.
[0189] In one embodiment, the efficacy value Eval can be used to manufacture an orally inhaled pharmaceutical product 1, e.g., by manufacturing a dry powder with a mean particle size corresponding to Aval, if the Aval value is well suited for pulmonary drug transport based on the evaluation of Eval. The particle size characterizing the dry powder corresponds to a mean particle size of the solid particles of the dry powder of the pharmaceutical product 1. The formulation of the pharmaceutical product 1 may contain excipients in addition to the active ingredient.
[0190] In further embodiments, the evaluation of the effectiveness could serve to manufacture, design and / or operate an inhaler device 2 such that it generates an aerosol 3 characterized by the value Aval, in particular by suitable choice of design parameters (e.g. a nozzle diameter) so that the inhaler device 2 generates an aerosol 3 with an aerosol parameter Apar corresponding to Aval.
[0191] In addition to the previously described advantages of the method, the method can also be applied to evaluate drug / device combination products 7 comprising an orally inhaled drug product 1 and an inhaler device 2, 2a-d. An example of a drug / device combination product 7 is a nebulizer inhaler device 2c having a canister 21 prefilled with an orally inhaled drug product 1 in liquid form. The drug product 1 is to be nebulized by the nebulizer inhaler device 2c to generate an aerosol 3 with a desired particle size that, according to the evaluation-based assessment, is well suited for pulmonary drug transport. Particularly in the initial phases of the development and approval process for new drug / device combination products, the Fig.The methods shown in Figure 11 provide reproducible, digital evidence that a new drug / device combination product 7 based on the same active ingredient as an approved drug product results in the same effective lung dose and similar spatial particle deposition distributions. For example, a series of different patient-specific lung models Lmod can be used to define a digital patient cohort and then conduct an in silico study following the described method to calculate digital biomarkers to predict or optimize target efficacy, dosage ranges, or population constraints.
[0192] If the described procedure is approved by regulatory authorities, it can also be applied in later phases of clinical trials to provide additional or supplementary information for regulatory approval of medicinal products. Furthermore, from a range of inhaler devices 2, the best inhaler device 2 can be selected for combination with a specific pharmaceutical product 1 to achieve drug delivery to a specific target region of the lung. Information can also be provided for modifying a specific inhaler device 2 or the associated inhalation protocol.
[0193] Examples of efficacy values Eval obtained for different aerosol values Aval and respiratory values Rval in different patient-specific lung models Lmod according to the described procedure are summarized in the following tables of Examples 1 and 2. Example 1:
[0194] For the first example study, the aerodynamic mass median diameter of aerosol particles 30 of an aerosol 3 was selected as the aerosol parameter Apar, using two different aerosol values Aval (3 µm and 6 µm, see left columns). Based on the calculated spatial particle deposition distribution Ddist, the effectiveness values Eval (see right columns) of the following effectiveness parameters Epar were calculated: The percentage of aerosol mass deposited in lung tissue as a proportion of the inhaled aerosol mass (Epar): aerodynamic mass median diameter [µm] Aerosol mass deposited in lung tissue as a proportion of the inhaled amount [%] 3 52 6 30
[0195] The percentage of aerosol mass deposited in the respiratory tract as a proportion of the inhaled aerosol mass (Epar): aerodynamic mass median diameter [µm] Aerosol mass deposited in the conducting airways as a proportion of the inhaled amount [%] 3 21 6 26
[0196] The percentage of deposited aerosol mass per airway generation expressed as a fraction of deposited aerosol mass (Epar). It can be deduced that the remainder of the deposited aerosol mass was transported to airway generations beyond 16, particularly to the alveolar level (49) and / or into the bloodstream (5).
[0197] The percentage of aerosol mass deposited in the lungs relative to the inhaled aerosol mass (Epar): aerodynamic mass median diameter [µm] Aerosol mass deposited in the lungs as a proportion of the inhaled amount [%] 3 73 6 56
[0198] The ratio between central and peripheral deposition (Epar), where "central" refers to a central area of the lung, while "peripheral" refers to the part of the lung surrounding the outer boundary of the central area. Regarding the structure of the airways, the central area mainly includes the lower generations of the conducting airways (i.e., the larger airways), while the peripheral area mainly includes the remaining higher generations (i.e., the smaller airways): aerodynamic mass median diameter [µm] Central / peripheral ratio [-] 3 0.2 6 0.25
[0199] The percentage of deposited aerosol mass per lung lobe as a proportion of deposited aerosol mass (Epar), e.g., in the upper lobe of the left lung 42 (left upper): aerodynamic mass median diameter [µm] Deposited aerosol mass per rag as a proportion of deposited mass [%] Top left Bottom left Bottom right Right middle Top right 3 19 24 26 8 16 6 17 23 26 6 12
[0200] The average deposited mass concentration in the lung [µg / ml] (Epar): aerodynamic mass median diameter [µm] Average concentration of deposited mass in the lung [µg / ml] 3 1.0 6 3.6 Example 2:
[0201] In a second exemplary study, the tidal volume of the lung [ml] was chosen as the respiratory parameter Rpar with two different respiratory values Rval (600 ml and 1000 ml). Based on the calculated spatial particle deposition distribution Ddist for a specific aerosol parameter Apar and aerosol value Aval (e.g., Apar: aerodynamic mass median diameter, Aval: 3 µm), efficacy values Eval (see right columns) of the following efficacy parameters Epar were calculated depending on two different respiratory values Rval (see left column):
[0202] The percentage of aerosol mass deposited in lung tissue as a proportion of the inhaled aerosol mass (Epar): Tidal volume [ml] Aerosol mass deposited in lung tissue as a proportion of inhaled aerosol [%] 600 54 1000 60
[0203] The percentage of aerosol mass deposited in the conducting airways as a proportion of the inhaled aerosol mass (Epar): Tidal volume [ml] Aerosol mass deposited in the conducting airways as a proportion of the inhaled amount [%] 600 23 1000 23
[0204] The percentage of deposited aerosol mass per airway generation as a proportion of deposited aerosol mass (Epar):
[0205] The percentage of aerosol mass deposited in the lungs relative to the inhaled aerosol mass (Epar): Tidal volume [ml] Aerosol mass deposited in the lungs as a proportion of the inhaled amount [%] 600 77 1000 83 The ratio between central and peripheral deposition (Epar): Tidal volume [ml] Central / peripheral ratio [-] 600 0.23 1000 0.2
[0206] The percentage of deposited aerosol mass per lobe as a proportion of deposited aerosol mass (Epar): Tidal volume [ml] Deposited aerosol mass per rag as a proportion of deposited mass [%] Top left Bottom left Bottom right Right middle Top right 600 30 25 29 18 22 1000 25 23 28 19 21
[0207] The average deposited mass concentration in the lung [µg / ml] (Epar): Tidal volume [ml] Average concentration of deposited mass in the lung [µg / ml] 600 0.67 1000 1.2
[0208] The experiments demonstrate that the efficacy for pulmonary drug transport can be accurately assessed, especially locally throughout the lung. Furthermore, the efficacy of drug delivery to a specific, predefined target area in the lung can be accurately assessed. List of reference numbers 1 medicinal product 2 Inhaler device 2a Dry powder inhaler device 2b Metered-dose inhaler device 2c Nebulizer inhaler device (soft mist inhaler device) 2d Inhaler device comprising a ventilation tube system 3 Aerosol 4 Respiratory system 4' discretized structure of the respiratory system 5 Blood circulation 6 Lung tissue 7 Inhaler / drug combination product 8 Thorax 20, 20' mouthpiece 21 canisters 22 nozzle 23 Aerosol generation chamber 24 ventilation circuit 24a first entrance 24b second inlet 24c outlet 25 Fogging device 26 propellants 27 Actuator 28 Actuator seat 29 Valve 30 aerosol particles 30' discrete particle 31 Carrier gas 40 Respiratory tract 40' airway segment 40a' upstream airway segment 40b', 40c' downstream airway segment 41 Mouth 42 lungs 43 Diaphragm 44 Pharynx 45 Larynx 46 Trachea 47 bronchi 48 bronchioles 49 alveoli 50, 50' airway wall 60 levers 61, 62 spring 63 wings 64 Activation mechanism 70 Dosing mechanism 71 Actuator cap 80 network 81 Deflection plate 82 Gas jet 83 vibrating component Img tomographic image Apar aerosol parameters Epar efficacy parameters Dopar inhaler operating parameters Ddpar inhaler design parameters Rpar respiratory parameters Aval aerosol value of the aerosol parameter Eval Efficacy value of the efficacy parameter Eval_min minimum value of the effectiveness parameter Eval_max maximum value of the effectiveness parameter Rval Respiratory value of the respiratory parameter Ddist spatial particle deposition distribution Dval deposit removal Wval distance value of the wall Gvel gas flow velocity Pvel vector of particle transport velocity Velprof speed profile Gf gravitational force Df resistance force of the flow (flow resistance) Bf buoyancy force BMf force of Brownian motion Mmod numerical mouth model Lmod numerical lung model Pmod numerical particle transport and deposition model Amod numerical absorption model Dmod numerical inhaler device model Lib Bifurc Airway branching library Bifurc1, Bifurc2, Bifurc3, ... Bifurc r pre-calculated airway branching scenario Dsub1, Dsub2, ..., Dsubn active ingredient dose Lungsubd1, Lungsubd2, ... Lungsubdn lung subdomains Centcomp central compartment Pcomp1, Pcomp2 peripheral compartment Muccl mucociliary clearance tMuccl, tsub1, tsub2 absorption half-life CLdcomp1, CLdcomp2, CL Clearance QUOTES CONTAINED IN THE DESCRIPTION
[0000] This list of documents submitted by the applicant was generated automatically and is included solely for the convenience of the reader. This list is not part of the German patent or utility model application. The DPMA assumes no liability for any errors or omissions. Cited patent literature
[0000] EP 2 255 843 A1 [0020, 0022, 0070] WO 2014 / 125059 A1 [0022, 0023, 0024] WO 2021 / 204931 A1 [0026, 0150] Zitierte Nicht-Patentliteratur
[0000] The New ICRP Model for the Respiratory Tract. Radiation Protection Dosimetry. 1994; 53(1-4):107-114. doi:10.1093 / rpd / 53.1-4.107
[0015] Taulbee DB, Yu CP. A theory of aerosol deposition in the human respiratory tract. Journal of Applied Physiology. 1975; 38(1):77-85. doi:10.1152 / jappl.1975.38.1.77
[0016] Taulbee DB, Yu CP, Heyder J. Aerosol transport in the human lung from analysis of single breaths. Journal of Applied Physiology. 1978; 44(5):803-812. doi:10.1152 / jappl.1978.44.5.803
[0016] Robinson RJ, Yu CP. Deposition of Cigarette Smoke Particles in the Human Respiratory Tract. Aerosol Science and Technology. 2001; 34(2):202-215. doi:10.1080 / 027868201300034844
[0016] Human respiratory tract model for radiological protection. A report of a Task Group of the International Commission on Radiological Protection. Ann ICRP. 1994; 24(1-3):1-482
[0017] Asgharian B, Hofmann W, Bergmann R. Particle Deposition in a Multiple-Path Model of the Human Lung. Aerosol Science and Technology. 2001; 34(4):332-339
[0017] Kronbichler M, Fehn N, Munch P, et al. A next-generation discontinuous Galerkin fluid dynamics solver with application to high-resolution lung airflow simulations. In: Proceedings of the International Conference for High Performance Computing, Networking, Storage and Analysis. SC '21. Association for Computing Machinery; 2021:1-15. doi:10.1145 / 3458817.3476171
[0021] De Backer JW, Vos WG, Vinchurkar SC, et al. Validation of Computational Fluid Dynamics in CT-based Airway Models with SPECT / CT. Radiology. 2010; 257(3):854-862. doi:10.1148 / radiol.10100322
[0024] Ismail M, Comerford A, Wall W A. Coupled and reduced dimensional modeling of respiratory mechanics during spontaneous breathing. International Journal of Numerical Methods in Biomedical Engineering 2013; 29:1285-1305
[0142] Bauer RJ, Guzy S, Ng C. A survey of population analysis methods and software for complex pharmacokinetic and pharmacodynamic models with examples. AAPS J. 2007; 9(1):E60-E83. doi:10.1208 / aapsj0901007
[0169]
Claims
[1] A method for evaluating the efficacy of an aerosol (3) for pulmonary drug delivery, the aerosol (3) comprising aerosol particles (30) containing an orally inhaled and / or nasal drug product (1), comprising the following steps: - determining at least one aerosol value (Aval) of at least one aerosol parameter (Apar) which characterises the aerosol (3), wherein the aerosol (3) is generated in particular by an inhaler device (2, 2a, 2b, 2c, 2d), - providing a numerical lung model (Lmod) representing the structure of a preferably human respiratory system (4) and the transient gas flow in the airways (40) of the respiratory system (4) at least between the trachea (46) and the lungs (42), in particular during inhalation and exhalation, wherein the numerical lung model (Lmod) is based on a discretized respiratory system structure (4') derived from processed image data representing at least one, preferably human, respiratory system (4), wherein preferably the discretized respiratory system structure (4') is derived from processed image data of a single tomographic image (Img) of each of the at least one respiratory system (4); - Providing a numerical particle transport and deposition model (Pmod) representing the transient transport of individual aerosol particles (30) in the gas flow in the respiratory tract (40) and the deposition of individual aerosol particles (30) in the respiratory system (4), - calculating a spatial particle deposition distribution (Ddist) of a plurality of discrete particles (30') deposited in the discretized respiratory system structure (4') based on the at least one aerosol value (Aval) using the numerical lung model (Lmod) and the numerical particle transport and deposition model (Pmod); - calculating at least one efficacy value (Eval) of an efficacy parameter (Epar) indicating the efficacy of the pulmonary drug transport of the aerosol (3) on the basis of the spatial particle deposition distribution (Ddist); - Using the efficacy value (Eval) to automatically evaluate efficacy for pulmonary drug transport, storing the efficacy value (Eval) in a storage device, displaying the efficacy value (Eval) using a display device, and / or transmitting the efficacy value (Eval) for use in evaluating efficacy for pulmonary drug transport. [2] Method according to claim 1, wherein the at least one aerosol parameter (Apar) indicates one or more of the following points - a particle size, preferably a medium particle size, - a particle size distribution, - a particle density, - a particle shape, preferably a medium particle shape, - an aerosol flow which is preferably time-dependent, in particular relative to a respiratory cycle, - a flow velocity of the aerosol, - a type of carrier gas and - the pressure of the aerosol carrier gas. [3] Method according to claim 1 or 2, wherein the at least one aerosol value (Aval) is determined by - measuring the aerosol value (Aval), - Obtaining the aerosol value (Aval) from a database containing data indicating the physical properties of the aerosol (3), - Obtaining or deriving the aerosol value (Aval) from the specification data of an inhaler device (2, 2a, 2b, 2c, 2d), - Calculating the aerosol value (Aval) based on analytical relationships of physical properties of the aerosol (3), and / or - Calculating the aerosol value (Aval), in particular as a result of a numerical simulation of a generation process and / or a flow of the aerosol (3), in particular in an inhaler device (2, 2a, 2b, 2c, 2d), preferably using a numerical inhaler device model (Dmod). [4] Method according to one of the preceding claims, further comprising a step of determining at least one respiratory value (Rval) of a respiratory parameter (Rpar) which characterizes the breathing of the respiratory system (4), in particular spontaneous breathing, assisted spontaneous breathing and / or artificial ventilation, wherein the respiratory value (Rval) defines a boundary condition of the numerical lung model (Lmod), wherein the respiratory parameter (Rpar) is preferably at least one of the following: - a, preferably time-dependent, pressure difference, preferably between a pleural space and the trachea (46), - a preferably time-dependent inhalation and / or exhalation gas flow, - a minimum and / or maximum value of the lung pressure and a value of a respiratory cycle frequency, in particular during pressure-controlled artificial ventilation, and - an inhalation and / or exhalation gas volume, particularly during volume-controlled artificial ventilation. [5] Method according to one of the preceding claims, wherein the discretized respiratory system structure (4') is based on a spatial segmentation of the structure of the, preferably conductive, airways (40) of the respiratory system (4) into a plurality of discrete, preferably spatially three-dimensional, further preferably tubular, airway segments (40', 40a', 40b', 40c') and preferably a temporal discretization of time steps, wherein preferably the gas flow velocity (Gvel) within at least a part of the airway segments (40', 40a', 40b', 40c') is constant for each time step. [6] Method according to one of the preceding claims, wherein the numerical lung model (Lmod) represents the structure of at least six, preferably at least eight, more preferably at least ten, more preferably at least twelve generations of airways (40), which preferably further represent the mouth (41), the pharynx (44) and / or the larynx (45), and which preferably further represent the alveoli (49) of the lungs (42), wherein the numerical lung model (Lmod) preferably represents a closed volume of the airways (40) and / or wherein the numerical lung model (Lmod) preferably represents the structural elasticity of the airways (40), in particular the structural elasticity of the airway walls (50) and / or the structural elasticity of the alveolar tissue. [7] Method according to one of the preceding claims, wherein the numerical lung model (Lmod) is based on - a discretized individual respiratory system structure (4') derived from processed image data representing an individual respiratory system (4), preferably of a healthy individual or of a patient suffering from a lung disease, or - a discretized averaged respiratory system structure (4') derived from, preferably averaged, processed image data representing an average of a plurality of, preferably individual, respiratory systems (4), preferably of at least one healthy individual and / or at least one patient suffering from a lung disease. [8] Method according to one of the preceding claims, wherein the numerical lung model (Lmod) is based on a discretized respiratory system structure (4') derived from processed image data representing at least one healthy respiratory system (4) and at least one predetermined pathological image data pattern representing a, preferably local, pathological change of at least one zone of the respiratory system (4) caused by a lung disease. [9] Method according to one of the preceding claims, wherein the numerical particle transport and deposition model (Pmod) implements a Lagrangian approach for tracking individual discrete particles (30') transported in the gas flow, in particular based on the modeling of at least one physical force acting on each individual discrete particle (30'), in particular a gravitational force (Gf), a drag force (Df), a buoyancy force (Bf) and / or a Brownian motion force (BMf), wherein in particular the direction of the gravitational force (Gf) in the numerical particle transport and deposition model (Pmod) is adjusted as a function of the spatial, preferably vertical or horizontal, orientation of the respiratory system (4) represented by the processed image data. [10] Method according to one of the preceding claims, wherein a discrete particle transport velocity field, in particular within a spatially three-dimensional airway segment (40', 40a', 40b', 40c'), has a higher spatial dimension than a discrete gas flow velocity field, in particular within the spatially three-dimensional airway segment (40', 40a', 40b', 40c'), wherein preferably a three-dimensional discrete particle transport velocity field within a spatially three-dimensional airway segment (40', 40a', 40b', 40c') is calculated based on a constant discretized gas flow velocity (Gvel) within the spatially three-dimensional airway segment (40', 40a', 40b', 40c'), at least within a part of the discretized respiratory system structure (4'), preferably within respiratory tract segments (40', 40a', 40b', 40c') belonging to at least a second, more preferably at least a third generation of the respiratory tracts (40) represented by the numerical lung model (Lmod). [11] Method according to one of the preceding claims, wherein the numerical particle transport and deposition model (Pmod) tracks individual discrete particles (30') within a spatially three-dimensional airway segment (40', 40a', 40b', 40c') by using a preferably three-dimensional particle transport velocity vector (Pvel) as the velocity of a particle (30'), wherein the particle transport velocity vector (Pvel) is preferably calculated on the basis of a predetermined three-dimensional velocity profile (Velprof) across the cross-section of the airway segment (40', 40a', 40b', 40c') and a preferably constant gas flow velocity (Gvel) obtained from the numerical lung model (Lmod) for the airway segment (40', 40a', 40b', 40c'). [12] Method according to one of the preceding claims, further comprising a step of inserting individual discrete particles (30') into the flow in the respiratory tract (40), comprising: - Assigning an insertion position in an inflow cross-section of the discretized respiratory system structure (4'), preferably in an inflow cross-section of the trachea (46), to each individual discrete particle (30'), and / or - Assigning a deployment time for each individual discrete particle (30') based on a specific aerosol flow, which is preferably time-dependent, in particular relative to a breathing cycle, wherein inserting individual discrete particles (30') further comprises assigning one or more of the following properties: Onset velocity, onset acceleration, particle density, particle size, particle shape, particle mass and drag coefficient for each individual discrete particle (30'), the insertion position is preferably determined based on the following criteria: - Obtaining or deriving a statistical spatial distribution of aerosol particles (30) in the aerosol (3), preferably based on measured, pre-calculated and / or randomly generated aerosol particle distribution data, - Calculating a particle location of the individual discrete particle (30') in a numerical simulation of a generation process and / or a flow of the aerosol (3), in particular in an inhaler device (2, 2a, 2b, 2c, 2d), preferably using a numerical inhaler device model (Dmod), and / or - Measuring the spatial distribution of aerosol particles (30) in the aerosol (3). [13] Method according to one of the preceding claims, wherein the numerical particle transport and deposition model (Pmod) determines the flow path of an individual discrete particle (30') across an airway branch (40a', 40b', 40c'), preferably during exhalation and / or inhalation, by assigning the particle (30') to a downstream airway segment (40b', 40c') based on the evaluation of at least one geometric branching criterion, wherein preferably a geometric branching criterion is based on a geometric relationship between an outflow cross-section of an upstream airway segment (40a') and an inflow cross-section of a downstream airway segment (40b', 40c'). [14] Method according to one of the preceding claims, wherein the numerical particle transport and deposition model (Pmod) determines the flow path of an individual discrete particle (30') across an airway branch (40a', 40b', 40c'), preferably during inspiration, using at least one pre-calculated airway branch scenario (Bifurc1, Bifurc2, Bifurc3, ... Bifurc r ), wherein preferably each pre-calculated airway branching scenario (Bifurc1, Bifurc2, Bifurc3, ... Bifurc r) is based on an evaluation of at least one previously performed higher-dimensional, preferably three-dimensional, simulation of the particle transport in the gas flow across a respiratory branch (40a', 40b', 40c'), wherein preferably the at least one pre-calculated airway branching scenario (Bifurc1, Bifurc2, Bifurc3, ... Bifurc r ) from an airway branching library (Lib Bifurc ) is obtained, in which preferably a plurality of different pre-calculated airway branching scenarios (Bifurc1, Bifurc2, Bifurc3, ... Bifurc r ) is stored. [15] Method according to one of the preceding claims, preferably according to 14, wherein a pre-calculated airway branching scenario (Bifurc1, Bifurc2, Bifurc3, ... Bifurc r) predicts the transport of a discrete particle (30') across an airway branch (40a', 40b', 40c') based on a classified type of branching geometry of the airway branch (40a', 40b', 40c') and / or based on a position of the discrete particle (30') in an upstream airway segment (40a'), preferably in a radial sector and / or in a circumferential sector of the upstream airway segment (40a'). [16] Method according to one of the preceding claims, preferably according to one of claims 14 or 15, wherein for determining the flow path of an individual discrete particle (30') across a specific airway branch (40a', 40b', 40c') a suitable pre-calculated airway branch scenario (Bifurc1, Bifurc2, Bifurc3, ... Bifurc r ), preferably from an airway branching library (Lib Bifurc ), based on at least one of the following: - a position, preferably radial position and / or circumferential position, of the discrete particle (30') in an upstream airway segment (40a'), - at least one geometric parameter indicating the geometry of the airway branching (40a', 40b', 40c'), - a particle size of the discrete particle (30'), - a particle density in the area of the airway branching (40a', 40b', 40c') and - a particle velocity upstream of the airway branch (40a', 40b', 40c'). [17] Method according to one of the preceding claims, wherein the numerical particle transport and deposition model (Pmod) determines the deposition of a discrete particle (30') based on the evaluation of at least one deposition criterion, wherein the evaluation of the deposition criterion preferably comprises at least one of the following criteria: - Evaluating whether a calculated distance value (Wdist) of the discrete particle (30') to an airway wall (50') of an airway segment (40', 40a', 40b', 40c') is equal to or less than a predetermined deposition distance (Dval), - Evaluating whether a calculated particle velocity (Pvel) of the discrete particle (30') is equal to or less than a predetermined minimum velocity, and / or - Evaluating whether a calculated angle of incidence between the flow path of the discrete particle (30') and an airway wall (50') of an airway segment (40', 40a', 40b', 40c') exceeds a predetermined minimum angle, which is preferably at least 45°, more preferably at least 60°, more preferably at least 75°. [18] Method according to one of the preceding claims, wherein the step of determining at least one aerosol value (Aval) uses a numerical inhaler device model (Dmod) representing a generation process and / or a flow of an aerosol (3) in an inhaler device (2, 2a, 2b, 2c, 2d), wherein the inhaler device (2, 2a, 2b, 2c, 2d) preferably comprises a dry powder inhaler device (2a), a metered-dose inhaler device (2b), a nebulizer inhaler device (2c) and / or an inhaler device (2d) having a ventilation tube system (24), wherein the numerical inhaler device model (Dmod) represents in particular one or more of the following elements - a particle size distribution of the aerosol, - a particle density of the aerosol, - a pressure of the carrier gas of the aerosol, preferably at the outlet from a mouthpiece (20) and / or a ventilation tube system (24) of the inhaler device (2, 2a, 2b, 2c, 2d), preferably time-dependent relative to a breathing cycle, - an aerosol flow, preferably at the outlet of a mouthpiece (20) and / or a ventilation tube system (24) of the inhaler device (2, 2a, 2b, 2c, 2d), preferably time-dependent with respect to a breathing cycle, and - a flow rate of the aerosol, preferably upon outlet from a mouthpiece (20) and / or a ventilation tube system (24) of the inhaler device (2, 2a, 2b, 2c, 2d), preferably time-dependent relative to a breathing cycle, preferably as a function of at least one or more of a selected device design parameter (Ddpar), a set device operating parameter (Dopar) and a breathing value (Rval) of a breathing parameter (Rpar) which influences the generation process and / or the flow of the aerosol (3) in the inhaler device (2, 2a, 2b, 2c, 2d). [19] Method according to one of the preceding claims, wherein the step of determining at least one aerosol value (Aval) uses a numerical inhaler device model (Dmod) representing the flow of an aerosol (3) in an inhaler device (2, 2a, 2b, 2c, 2d), wherein the numerical inhaler device model (Dmod) preferably represents at least one component of the inhaler device (2, 2a, 2b, 2c, 2d) characterized by at least one device design parameter (Ddpar), wherein the device design parameter (Ddpar) preferably indicates at least one of the following: - a shape of a mouthpiece (20) and / or a ventilation tube system (24) of the inhaler device (2, 2a, 2b, 2c, 2d), - a diameter and / or a shape of a nozzle (22) of the inhaler device (2, 2a, 2b, 2c, 2d), - a flow channel geometry from an outlet of an aerosol generation and / or aerosol storage chamber (23) to an outlet, preferably of a mouthpiece (20) and / or a ventilation hose system (24), of the inhaler device (2, 2a, 2b, 2c, 2d), and - a volume and / or a geometry of a container (21) containing a preferably liquid, orally inhaled and / or nasal pharmaceutical product (1). [20] Method according to one of the preceding claims, where the efficacy parameter (Epar) indicates at least one of the following: - an effective dose, preferably locally, - a, preferably local, density of the deposited aerosol particles (30) and - a concentration, preferably local, of an active ingredient of the orally inhaled and / or nasal medicinal product (1). [21] Method according to one of the preceding claims, wherein the aerosol particles (30) contain a predetermined dose of an active ingredient of the orally inhaled and / or nasal pharmaceutical product (1), wherein preferably the efficacy parameter (Epar) indicates a blood concentration of the active ingredient in the blood and the calculation of at least one value (Eval) of the blood concentration preferably uses a numerical absorption model (Amod) which represents the absorption of the active ingredient contained in the aerosol particles (30) into a bloodstream (5), and / or wherein preferably the efficacy parameter (Epar) indicates a tissue concentration of an active ingredient in the lung tissue and the calculation of at least one value (Eval) of the tissue concentration preferably uses a numerical absorption model (Amod) which represents the absorption of the active ingredient contained in the aerosol particles (30) into a lung tissue (6). [22] Method according to one of the preceding claims, comprising the following further steps: - determining a predetermined minimum effectiveness value (Eval_min) of the effectiveness parameter (Epar); - Using the determined at least one aerosol value (Aval) as a starting value; - adjusting the aerosol value (Aval), preferably in an iterative loop in which at least some of the steps of the method according to one of the preceding claims are repeatedly carried out until the calculated effectiveness value (Eval) is equal to or greater than the predetermined minimum effectiveness value (Eval_min); and - storing the adjusted aerosol value (Aval) in a storage device, outputting the adjusted aerosol value (Aval) to a display device and / or providing the adjusted aerosol value (Aval) for use in evaluating the efficacy for pulmonary drug transport as an optimized aerosol value (Aval) of the aerosol parameter (Apar). [23] Method according to one of the preceding claims, wherein the at least one aerosol value (Aval), in particular when the at least one efficacy value (Eval) is equal to or greater than a predetermined minimum efficacy value (Eval_min) of the efficacy parameter (Epar) and preferably less than a predetermined maximum efficacy value (Eval_max) of the efficacy parameter (Epar), is used for at least one of the following: - generating an aerosol (3) comprising aerosol particles (30) containing an orally inhaled and / or nasal pharmaceutical product (1), preferably using an inhaler device (2, 2a, 2b, 2c, 2d), wherein the aerosol (3) is characterized by the aerosol value (Aval), - setting a device operating parameter (Dopar) of an inhaler device (2, 2a, 2b, 2c, 2d) so that the inhaler device (2, 2a, 2b, 2c, 2d) produces an aerosol (3) characterized by the aerosol value (Aval), and - designing and / or manufacturing an inhaler device (2, 2a, 2b, 2c, 2d) which is designed to generate an aerosol (3) which is characterized by the aerosol value (Aval), and - Producing an orally inhaled and / or nasal pharmaceutical product (1), preferably in the form of a dry powder, characterized by the aerosol value (Aval) of the aerosol parameter (Apar), which is preferably a particle size, a mean particle size and / or a particle size distribution. [24] Method according to one of the preceding claims, wherein the at least one effectiveness value (Eval), in particular if the at least one effectiveness value (Eval) is greater than a predetermined minimum effectiveness value (Eval_min) of the effectiveness parameter (Epar) and preferably less than a predetermined maximum effectiveness value (Eval_max) of the effectiveness parameter (Epar), is used for at least one of the following: - Evaluating the performance of an inhaler device (2, 2a, 2b, 2c, 2d) for pulmonary drug transport, in particular the effect of a setting of a device operating parameter (Dopar) and / or the effect of a device design parameter (Ddpar) of the inhaler device (2, 2a, 2b, 2c, 2d) on the performance for pulmonary drug transport, wherein the inhaler device (2, 2a, 2b, 2c, 2d) is configured, in particular when operated with a predetermined setting of a device operating parameter (Dopar), to generate an aerosol (3) for pulmonary drug transport, such that the aerosol (3) is characterized by the aerosol value (Aval) of the aerosol parameter (Apar), - Evaluating the efficacy and / or safety of an orally inhaled and / or nasal pharmaceutical product (1), in particular a dose of an active ingredient of an orally inhaled and / or nasal pharmaceutical product (1), for pulmonary drug transport, wherein the orally inhaled and / or nasal pharmaceutical product (1) is prepared for administration in the form of an aerosol (3), preferably using an inhaler device (2, 2a, 2b, 2c, 2d), characterized by the aerosol value (Aval) of the aerosol parameter (Apar), and - Evaluating the efficacy of a drug / device combination product (7) comprising an orally inhaled and / or nasal drug product (1) and an inhaler device (2, 2a, 2b, 2c, 2d) for pulmonary drug transport, wherein the orally inhaled and / or nasal drug product (1) is prepared for administration in the form of an aerosol (3) characterized by the aerosol value (Aval) using the inhaler device (2, 2a, 2b, 2c, 2d), in particular when operated with a predetermined setting of a device operating parameter (Dopar), and the inhaler device (2, 2a, 2b, 2c, 2d) is configured to generate an aerosol (3) characterized by the aerosol value (Aval) of the aerosol parameter (Apar), in particular when operated with a predetermined setting of a device operating parameter (Dopar). [25] A method for evaluating the performance of a pulmonary drug delivery inhaler device (2, 2a, 2b, 2c, 2d), the inhaler device (2, 2a, 2b, 2c, 2d) being adapted to generate an aerosol (3) comprising aerosol particles (30) containing an orally inhaled and / or nasal drug product (1), the performance of the pulmonary drug delivery inhaler device (2, 2a, 2b, 2c, 2d) being evaluated as a function of the efficacy of the pulmonary drug delivery aerosol (3) when evaluated according to any one of the preceding claims. [26] A method for evaluating the efficacy and / or safety of an orally inhaled and / or nasal pharmaceutical product (1) for pulmonary drug delivery, wherein the orally inhaled and / or nasal pharmaceutical product (1) is prepared for administration in the form of an aerosol (3), preferably using an inhaler device (2, 2a, 2b, 2c, 2d), wherein the efficacy of the orally inhaled and / or nasal pharmaceutical product (1) for pulmonary drug delivery is evaluated as a function of the efficacy of the aerosol (3) for pulmonary drug delivery when evaluated according to any one of the preceding claims. [27] A method for evaluating the efficacy of a drug / device combination product (7) comprising an orally inhaled and / or nasal drug product (1) and an inhaler device (2, 2a, 2b, 2c, 2d) for pulmonary drug delivery, wherein the inhaler device (2, 2a, 2b, 2c, 2d) is designed to generate an aerosol (3) comprising aerosol particles (30) containing the orally inhaled and / or nasal drug product (1), and the orally inhaled and / or nasal drug product (1) is adapted for administration in the form of the aerosol (3) using the inhaler device (2, 2a, 2b, 2c, 2d), wherein the efficacy of a drug / device combination product (7) for pulmonary drug delivery is evaluated as a function of the efficacy of the aerosol (3) for pulmonary drug delivery when said assessed according to any one of the preceding claims. [28] A computer program product comprising instructions which, when executed by a computer, cause the computer to perform at least some steps of the method according to any one of the preceding claims. [29] A computer-readable medium comprising instructions, the instructions, when executed by a computer, implementing at least some steps of the method according to any one of claims 1 to 27. [30] A method for generating an aerosol (3) comprising aerosol particles (30) containing an orally inhaled and / or nasal pharmaceutical product (1) using an inhaler device (2, 2a, 2b, 2c, 2d), the method comprising the following steps: - carrying out the method according to one of the preceding claims; - Providing an orally inhaled and / or nasal pharmaceutical product (1), in particular based on an efficacy evaluation according to one of the preceding claims, in particular when the at least one efficacy value (Eval) is equal to or greater than a predetermined minimum efficacy value (Eval_min) of the efficacy parameter (Epar); - Providing an inhaler device (2, 2a, 2b, 2c, 2d), in particular based on an efficacy evaluation according to one of the preceding claims, in particular if the at least one efficacy value (Eval) is equal to or greater than a predetermined minimum efficacy value (Eval_min) of the efficacy parameter (E-par); - supplying the orally inhaled and / or nasal medicinal product (1) to the inhaler device (2, 2a, 2b, 2c, 2d); - Operating the inhaler device (2, 2a, 2b, 2c, 2d), preferably by setting a device operating parameter (Dopar) of the inhaler device (2, 2a, 2b, 2c, 2d) according to an efficacy evaluation according to one of the preceding claims, in particular when the at least one efficacy value (Eval) is equal to or greater than a predetermined minimum efficacy value (Eval_min) of the efficacy parameter (Epar), so that the inhaler device (2, 2a, 2b, 2c, 2d) generates an aerosol (3) characterized by the aerosol value (Aval) of the aerosol parameter (Apar). [31] A method for designing and / or manufacturing an inhaler device (2, 2a, 2b, 2c, 2d) adapted to generate an aerosol (3) comprising aerosol particles (30) containing an orally inhaled and / or nasal pharmaceutical product (1), the method comprising the following steps: - selecting at least one value of a device design parameter (Ddpar) characterizing an inhaler device (2, 2a, 2b, 2c, 2d); - carrying out the method according to one of the preceding claims, preferably according to claim 19; - Designing and / or manufacturing an inhaler device (2, 2a, 2b, 2c, 2d), in particular based on an efficacy evaluation according to one of the preceding claims, in particular if the at least one efficacy value (Eval) is equal to or greater than a predetermined minimum efficacy value (Eval_min) of the efficacy parameter (Epar), so that the inhaler device (2, 2a, 2b, 2c, 2d) implements the selected value of the device design parameter (Ddpar). [32] Inhaler device (2, 2a, 2b, 2c, 2d) for administering orally inhaled and / or nasal medicament products (1), which is designed and / or manufactured by carrying out the method steps of claim 31. [33] Inhaler device (2, 2d) according to claim 32, wherein the inhaler device (2, 2d) comprises a ventilation tube system (24) for administering orally inhaled and / or nasal medicament products (1) to artificially ventilated patients, wherein the ventilation tube system (24) preferably comprises a first inlet (24a) for an aerosol flow and a second inlet (24b) for a ventilation gas flow generated by a ventilation device and preferably further comprises a common outlet (24c) for the aerosol flow and the ventilation gas flow. [34] A process for the preparation of an orally inhaled and / or nasal pharmaceutical product (1), preferably in the form of a dry powder, comprising - Carrying out the method according to one of the preceding claims, wherein preferably a particle size characterizing the dry powder is selected as the determined aerosol value (Aval); - Producing an orally inhaled and / or nasal pharmaceutical product (1), preferably in the form of a dry powder, in particular based on an efficacy evaluation of an aerosol (3) characterized by the determined aerosol value (Aval) according to one of the preceding claims, in particular when the at least one efficacy value (Eval) is equal to or greater than a predetermined minimum efficacy value (Eval_min) of the efficacy parameter (Epar), so that the orally inhaled and / or nasal pharmaceutical product (1) is prepared for administration in the form of an aerosol (3) characterized by the aerosol value (Aval) of the aerosol parameter (Apar) using an inhaler device (2, 2a, 2b, 2c, 2d). [35] Orally inhaled and / or nasal pharmaceutical product (1), in particular dry powder, obtained by carrying out the process steps according to claim 34. [36] A drug / device combination product (7) comprising an orally inhaled and / or nasal drug product (1) and an inhaler device (2, 2a, 2b, 2c, 2d) for administering orally inhaled and / or nasal drug products (1), wherein the drug / device combination product (7) comprises an orally inhaled and / or nasal drug product (1) according to claim 35 and / or an inhaler device (2, 2a, 2b, 2c, 2d) according to claim 32 or 33.
Citation Information
Patent Citations
Method for determining treatments using patient-specific lung models and computer methods
EP2255843A1
Method for determining a respiratory condition based on functional respiratory imaging
WO2014125059A1
Method, computer program, system and ventilator, for determining patient-specific respiratory parameters on a ventilator
WO2021204931A1
